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Abstract  
Alzheimer disease is considered to be a progressive neurodegenerative condition, 
clinically characterized by cognitive dysfunction and memory impairments. Incorporating 
imaging biomarkers in the early diagnosis and monitoring of disease progression is 
increasingly important in the evaluation of novel treatments. The purpose of the work in 
this thesis was to develop and evaluate novel structural and functional biomarkers of 
disease to improve Alzheimer disease diagnosis and treatment monitoring. The 
overarching hypothesis is that magnetic resonance imaging methods that sensitively 
measure brain structure and functional impairment have the potential to identify people 
with Alzheimer’s disease prior to the onset of cognitive decline.  Since the hippocampus 
is considered to be one of the first brain structures affected by Alzheimer disease, in the 
first study a reliable and fully automated approach was developed to quantify medial 
temporal lobe atrophy using magnetic resonance imaging.  This measurement of medial 
temporal lobe atrophy showed differences (p<0.05) between groups of healthy people, 
people with mild cognitive impairment and people with Alzheimer disease.  In the second 
study, a novel biomarker of brain activity was developed based on a first-order textural 
feature of the resting state functional magnetic resonance imagining signal. The mean 
brain activity metric was shown to be significantly lower (p<0.05) within specific brain 
regions in people with Alzheimer’s disease compared to healthy subjects and was 
correlated with cognitive performance and CSF biomarkers.  Interestingly, this brain 
activity metric was also correlated (p<0.05) with glucose metabolism in each subject 
measured using 18F labeled fluorodeoxyglucose positron emission tomography. In the 
 
ii 
final study, we examine whether combined measures of gait and cognition could predict 
medial temporal lobe atrophy over 18 months in a small cohort of people (N= 22) with 
mild cognitive impairment.  The results showed that measures of gait impairment can 
help to predict medial temporal lobe atrophy in people with mild cognitive impairment.  
The work in this thesis contributes to the growing evidence that specific magnetic 
resonance imaging measures of brain structure and function can be used to identify and 
monitor the progression of Alzheimer’s disease.  Continued refinement of these methods, 
and larger longitudinal studies will be needed to establish whether the specific metrics of 
brain dysfunction developed in this thesis can be of clinical benefit and aid in drug 
development.  
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Chapter 1: Thesis Introduction 
The overall goal of this thesis is to develop and evaluate novel structural and 
functional magnetic resonance imaging (MRI) biomarkers of Alzheimer’s disease. Such 
biomarkers are required to monitor disease progression and may help identify people at 
risk for the disease. The search for sensitive and specific early indicators of Alzheimer’s 
disease (AD) prior to symptom onset has intensified over the last decade.  The work in 
this thesis contributes to a growing literature that has identified specific structural and 
functional abnormalities in the brain associated with AD and Mild Cognitive Impairment 
(MCI).  Specifically, in the first study a novel tissue segmentation method was developed 
to characterize volume changes in the medial temporal lobe (mainly hippocampus) in 
subjects with MCI and AD. In the second study a new biomarker of neuronal activity was 
developed using blood oxygen level dependent (BOLD) contrast fluctuation during 
resting state functional MRI and was used to demonstrate reduced activity in subjects 
with AD compared to healthy controls. Finally, in the third study the medial temporal 
lobe segmentation method developed in the first study was used to classify a cohort of 
MCI subjects as stable or in decline to determine whether measures of gait and cognition 
could predict MTL atrophy over 18 months.  This first chapter introduces the 
neuropathology, diagnosis and clinical assessment of AD, and imaging biomarkers 
currently in development to predict the early stages of the disease, and to evaluate disease 
progression. This chapter also provides a background to image registration and 
segmentation theory, and describes aspects of MRI relevant to the processing and 
analysis chapters that follow.  
 
 
2 
1.1 Alzheimer Disease 
Alzheimer disease (AD) is a progressive neurodegenerative disease of the brain and 
is the most common cause of dementia. AD causes symptoms of dementia such as 
memory loss, difficulty performing daily activities, and changes in judgement, reasoning, 
behaviour, and emotions. There are three main categories of AD.  First is familial AD 
(FAD), which is caused by mutations in specific genes. The second is early-onset AD, 
which affects people younger than 65. The third is late-onset AD, which appears in adults 
aged 65 and older (Alzheimer society of Canada, 2014). AD affects approximately 10% 
of people who are less than 65 years old and the incidence approximately doubles every 5 
years up to age 80.1 Current estimates suggest half a million Canadian individuals are 
diagnosed with AD and 24 million people are afflicted by AD worldwide (Alzheimer’s 
Society of Canada, January 2009). AD progresses gradually and is classified into three 
main stages based on the symptoms. The early (mild) stage corresponds to the first 
diagnosis of the disease and usually lasts for 2 to 4 years. Common symptoms include 
difficulty recalling new information, problem solving, and subtle personality changes. 
The moderate stage is the longest in duration and typically lasts 2 to 10 years. Subjects 
have increased difficulty with memory and may need help with their daily activities. 
Usual symptoms include increasingly poor judgment, difficulty performing complex 
tasks, greater memory loss and significant personality changes. The last stage is the most 
severe and usually lasts 1 to 3 years. Cognitive function and physical ability are 
significantly impacted. Common symptoms include the inability to communicate, 
difficulty with personal care, and the inability to perform basic physical functions.2,3 
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AD is the only cause of death among the top 10 causes that has no known prevention 
or cure.4,5 Future morbidity and mortality of people with AD could be reduced by 
defining reliable diagnostic biomarkers that could be used to detect the disease early. 
Early knowledge of the disease should provide people with an opportunity to modify the 
progression of the disease if and when there is an effective treatment developed. Figure 
1.1 provides a schematic overview of brain structure labeled with associated functions. 
 
1.2 Mild Cognitive Impairment 
Mild cognitive impairment (MCI) is a transitional stage between normal aging and 
Alzheimer disease and is considered by some to be a symptomatic pre-dementia phase. 
Cognitive and behavioral impairment is characterized by impairment within a minimum 
of two cognitive domains: memory, executive function (e.g. reasoning, problem solving, 
planning), language (e.g. naming, fluency, expressive speech), attention, and visuospatial 
skills (e.g. simple and divided attention).6 Impairment in episodic memory is one of the 
clinical indicators7 of MCI and is a strong predictor of conversion to AD.   
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Figure 1.1 Anatomy of brain structures in sagittal view  
This schematic shows 4 lobes and structures in the brain along with their functions.[1] 
 
The number of people with MCI aged 75 years and younger is 19%, while 29% of 
people who are 85 years and older are characterized by a cognitive decline without 
impairment in the performance of the activities of daily living.8 The prevalence of 
amnestic MCI (aMCI) diagnosed by memory impairment and delayed recall but normal 
test result on other cognitive domains9,10 is 30% among individuals with MCI. The 
incidence of conversion of aMCI to AD is approximately 12% each year, and up to 80% 
have progression to AD after 6 years.9 Therefore, it is imperative that accurate methods 
are developed to identify subjects with MCI that will progress to AD so that when 
developed, disease-modifying treatment could be used to avoid significant brain damage. 
                                                
[1] Adapted with permission from: // http://www.brainwaves.com/ 
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1.3 Neuropathology 
Theories about the neuropathology of AD involve mostly two specific proteins: 
amyloid beta (Aβ) and tau.  Specifically, these two proteins lead to the formation of Aβ 
plaques and neurofibrillary tangles (NFT), which accumulate abnormally11,12 during 
aging and in AD. The prevalence of the aggregation increases gradually with age and 
these remain the main pathological hallmarks of the disease.  
Aβ plaques are found outside of neurons (extracellular) and consist of Aβ peptides 
with 40-42 amino acids (Aβ40 and Aβ42). Aβ peptides are produced by metabolism of the 
amyloid precursor proteins (APPs) that are cleaved by the enzymes β- and γ-secretases in 
the neuron.13,14 Soluble Aβ monomers aggregate into oligomers and re-arrangement of 
these oligomers produce β-sheets and fibrils.15 Aβ plaques are divided into two groups 
called diffuse and dense (neuritic) based on their staining with dyes specific for the β-
sheet (e.g., Congo red and Thioflavin-S).14,16 Dense plaques are stained with dyes but 
diffuse plaques are negative. Diffuse plaques are non-fibrilar accumulations of Aβ and 
are not associated with detectable dystrophic neurites, synaptic loss, or neuron loss. 
Diffuse plaques are also found in the cortex of cognitively normal aged people.17 While 
dense plaques contain fibrilary Aβ and are surrounded by degenerating axons and 
dendrites that are most often found in AD subjects. Aβ plaques are toxic in close 
proximity to nerve cells and promote the hyperphosphorylation of the tau protein.  
The aggregation of hyperphosphorylated tau protein leads to the formation of NFTs 
inside neurons (intracellular). Tau is a phosphorprotein normally localized to the axon, 
where it physiologically aids in axonal transport by binding and stabilizing the 
microtubules in the cell cytoskeleton. In AD patients, tau is displaced to the 
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somatodendritic compartment and undergoes hyperphosphorylation, misfolding, and 
aggregation in neurons. Paired helical filaments are the predominant form of NFTs.18 
The overall effects of Aβ plaques and NFTs are to produce synaptic failure and 
neuronal loss, which are the main pathological hallmarks of AD. This link is critical since 
brain structure and atrophy can be measured using MRI. Cortical atrophy occurs 
gradually and eventually produces declines in cognitive and executive function.12 Figure 
1.2 summarizes the steps involved in the process of Aβ aggregation and NFTs 
accumulation in AD. Previous studies have shown an association between the number of 
NFT and neuronal loss;19 as well as between Aβ plaque accumulation and neuronal loss.20 
Aβ accumulation includes three stages based on the Braak and Braak staging system.17,21 
During Stage A, initial depositions can be found in the basal portions of the frontal, 
temporal and occipital lobes. During Stage B, all isocortical areas are affected and the 
hippocampal formation is mildly involved. But, in this stage, the primary sensory and 
motor areas contain none or only small deposits. Stage C is the last stage in which 
depositions are found in all areas of the isocortex including visual, sensory and motor 
cortex.Based on the Braak and Braak staging system,21 NFT depositions appear first in 
the trans-entorhinal region of the temporal lobe, and lateral to the hippocampus (stages I 
and II) then spread to the limbic area (stages III and IV), and finally to isocortical areas 
(stages V and VI). The progression of regional tau deposition is closely coupled with the 
profile of neurocognitive impairment observed in AD.22,23 In addition, NFT accumulation 
is more strongly correlated with the severity of cognitive decline compared to Aβ plaques 
depositions.14,24 Figure 1.3 demonstrates the Braak and Braak staging of Aβ aggregation 
and NFT accumulation during aging. 
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Figure 1.2 The accumulation of Aβ and NFTs in the AD brain 
Aβ aggregates surround neurons and neurofibrillary tangles (NFTs) deposit inside neurons. Both 
pathologies are associated with dementia.[2] Aβ peptides are produced by metabolism of the 
amyloid precursor protein (APPs) that is enzymatically cleaved. Aβ monomers aggregate into 
oligomers and re-arrangement of these oligomers produce Aβ fibrils and plaques. Tau becomes 
hyperphosphorylated, misfolds, and aggregates in neurons. Paired helical filaments of tau are the 
predominant constituents of NFTs. The overall effect of Aβ plaques and NFTs is to produce 
synaptic failure and neuronal loss. 
 
 
 
                                                
[ 2 ] Adapted from Dementia & Neuropsychologia, 3 (2009), V. Paula And F. M. 
Guimaraes, Neurobiological pathways to Alzheimer’s disease Amyloid-beta, Tau protein 
or both?, 118-194, © 2016 
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Figure 1.3 Neuropathology of NFT and Aβ accumulation during aging 
Images adopted from Braak and Braak stages.25 The first row indicates the frequency of cases 
devoid of changes in relation to the total number of cases in the various age categories. The 
second, third, and fourth rows show the progression of amyloid (left panel) and NFT (right panel) 
changes during stages (A-C and I-VI). Stages (A) include basal portions of isocortex, (B) 
neocortical areas and the hippocampus, and (C) primary areas of the neocortex. Stages (I, and II) 
include transentorhinal region, (III, and IV) limbic system and severe involvement in 
transentorhinal and entorhinal regions, (V, and VI) isocortical area.[3] 
 
1.4 Diagnosis and Clinical Assessment 
The diagnosis of AD is only confirmed by brain autopsy after death. However, the 
National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) 
and the Alzheimer’s Disease and Related Disorders Association (ADRDA) established 
                                                
[3] Adapted from Neurobiology of Aging, 18 (1996), H. Braak And E. Braak, Frequency 
of Stages of Alzheimer-Related Lesions in Different Age Categories, 351-357, © 2016, 
with permission from Elsevier 
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and described the clinical criteria for AD diagnosis.6 The clinical diagnosis of AD 
combines cognitive tests, with physical and neuropsychological exams. Neurological 
examination and laboratory tests of thyroid imbalanced calcium and vitamin B12 levels 
also help to exclude other causes of dementia.26 The cognitive tests allow physicians to 
evaluate changes in cognition in the individual over time. Examples of clinical 
neuropsychological assessments include: Rey Auditory Verbal Learning Test (episodic 
memory),27 the Trail Making Test B (executive function),28,29 Digit Span 
Forward/Backward and Trail Making Test A (attention and processing),29,30 the Boston 
Naming Test (language)31 and Figure Copying (visuospatial skills)32 to assess different 
cognitive domains.  The evidence of progressive changes of all tests over time is an 
important component for accurate diagnosis. The sensitivity of AD diagnosis based on 
clinical confidence levels and neuropathological confidence levels varied from 70.9% to 
87.3% with specificity ranged from 44.3% to 70.8%.33 Therefore, although such 
cognitive testing can help to identify people with AD, diagnostic accuracy might be 
improved by the incorporation of additional biomarkers including cerebral spinal fluid 
(CSF) and neuroimaging biomarkers. 
One of the most common clinical cognitive tests is the mini mental state examination 
(MMSE). It is used for diagnosis and to monitor the progression of cognitive 
performance over time.34 The test consists of 11 questions and assesses five cognitive 
domains including orientation, registration, attention, recall, and language. The maximum 
score is 30 and a score of 23 or lower indicates cognitive impairment. The second clinical 
cognitive test that is commonly used is the Alzheimer disease assessment scale-cognitive 
(ADAS-Cog)35 which includes 11 items involving memory, orientation, language, and 
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praxis. This score ranges from 70 (severe impairment) to 0 (no impairment). The MMSE 
score has high test-retest reliability, which varies from 0.79 to 0.99.36 Although the 
MMSE score is insensitive to MCI37 and has only modest sensitivity to AD with little 
diagnostic specificity38 it is still widely used in clinical settings. 
 
1.5 Biomarkers of Alzheimer Disease 
A biomarker refers to a measurable indicator of a biological, pathogenic, or 
pharmacologic processes that can be used to increase diagnostic sensitivity and 
specificity. Biomarkers are particularly critical for early disease detection, disease 
staging, and monitoring of disease progression or treatment responses.39 Biomarkers may 
be divided into three different categories in relation to the diagnosis of AD. First, some 
hallmarks directly reveal the molecular neuropathology of AD. For example, Aβ plaques 
and NFT are established hallmarks of the pathological diagnosis of AD. These proteins 
can be measure directly from CSF or positron emission tomography (PET) scanning with 
several tracers.40-42 Second, biomarkers associated with neural loss and synaptic failure 
can be obtained from structural and functional measurements.  These include global and 
regional brain atrophy measurements using MRI and glucose metabolism measurements 
using PET.43-45 The third group is related to biochemical changes including inflammation 
and oxidative stress that can be detected using CSF, plasma, and imaging markers.46 
Importantly, biomarkers can be used to indicate relevant information about the 
underlying disease pathology before the cognitive symptoms progress to dementia.47,48 
Biomarkers including cerebral spinal fluid (CSF) Aβ, tau, and p-tau levels, and imaging 
methods of brain amyloid, metabolism, and atrophy do not as of yet have standardized 
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protocols in place and are mainly applied in research settings.49 The accumulation of 
NFTs and Aβ can be measured in CSF and serum;50 the level in CSF is related to cerebral 
Aβ aggregation (lower CSF Aβ) and NFT deposits (increased CSF tau, p-tau). The CSF 
biomarkers (Aβ1-42, tau and phospho-tau-181) represent a method with high sensitivity 
and specificity of 85% to 90% for the diagnosis of AD.51-54 CSF reveals metabolic 
processes in the brain due to the close proximity between the brain and CSF. However, 
the use of CSF biomarkers is limited because it requires an invasive assessment by 
lumbar puncture.51 
In addition, PET scanning with a variety of tracers now provides a tool to directly 
detect NFTs and Aβ accumulation in the brain. The success of PET Aβ imaging with 
Pittsburgh compound B (PiB) has translated into the clinical setting as a promising 
biomarker.55 Recently, many AD clinical and research settings have applied Aβ PET 
imaging, and an effort has been made to obtain FDA approval for the use of amyloid PET 
tracers in the diagnosis of AD and other dementias.56 However, the challenge with PiB is 
related to the stability of the 11C radioisotope due to its short half-life of only 20 minutes. 
Recently, alternative Aβ tracers have been developed including (E)-4-(2-(6-(2-(2-(2-
[18F]-fluoroethoxy) ethoxy) ethoxy) pyridin-3-yl) vinyl) -N-methyl benzenamine 
(Florbetapiror [18F]-AV-45) and Trans-4-(N-Methylamino)-4´-(2-[2-(2-[18F] fluoro-
ethoxy) ethoxy] ethoxy) stilbene ([18F]-BAY94-9172)57 with a half-life of 110 minutes 
making it more accessible to imaging sites.58 New tau PET tracers can also be used to aid 
in diagnosis and monitoring of disease progression. Tau PET tracers have at least two 
distinct forms; non-selective tau tracers that binds to both extracellular Aβ plaques and 
intracellular neurofibrillary tangles, and selective tau PET tracers that are highly selective 
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for tau over Aβ. For example, Barrio and colleagues developed and showed that 2-(1-(6-
[(2-[18F] fluoroethyl) (methyl) amino]-2-naphthyl) ethylidene) malononitrile ([¹⁵F]-
FDDNP), can bind to both intercellular neurofibrillary tangles and extracellular Aβ 
plaques in AD subjects.59,60 While, 6-[(3-[¹⁵F] fluoro-2-hydroxy) propoxy]-2-(4-
dimethylaminophenyl) quinolone ([¹⁵F]-THK5105) and 6-[(3-[¹⁵F]fluoro-2-hydroxy) 
propoxy]-2-(4-methylaminophenyl) quinolone ([¹⁵F]-THK5117) are 18F-labeled 
arylquinoline derivative examples of selective tau PET tracers and have been shown to 
have higher binding to tau over Aβ in AD.61,62 The combination of tau and Aβ PET 
imaging will improve the specificity of diagnosis and potentially the early detection of 
the pathology of AD. However, these tracers require more validation for use in research 
and clinical centers.  The development and assessment of new and better performing 
tracers could provide insight into the causes and treatment of tauopathies such as AD.  
The measurement of cerebral glucose metabolism rate with flurodeoxyglucose (18F) 
positron emission tomography (FDG-PET) and perfusion in temporo-parietal cortex 
using single photon emission tomography (SPECT) imaging have also contributed 
substantially to understanding brain functional activity. FDG-PET was the most widely 
used PET technique in AD, before the development of Aβ PET ligands. For over 20 years 
in AD subjects, FDG-PET has been used to measure cerebral metabolic rates of glucose 
(CMRglc) as an indicator of neuronal activity.56 Structural imaging using MRI can also 
be used to measure region of interest (ROI) changes in tissue volume such as the 
hippocampus.63-65 
In summary, functional and structural biomarkers provide information about 
underlying disease pathology, and the topography of neuronal damage and synaptic 
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degeneration in AD.  Such biomarkers include hippocampal volume, or other measures of 
brain atrophy by MRI, FDG-PET imaging of glucose metabolism, and SPECT perfusion 
imaging. These markers of neuronal injury may provide important measures of the brain 
during the symptomatic disease stage. In contrast, molecular hallmarks directly reflect 
AD neuropathology66 and can provide additional information during the asymptomatic 
phase of the disease. Structural and functional biomarkers are more associated with 
cognitive function over time than the molecular hallmarks.67,68 Jack and et. al.69 proposed 
that the clinical disease stage (cognitively normal, mild cognitive impairment and 
dementia) is associated with the amplitude of various biomarkers. For example, CSF Aβ 
and amyloid PET measures are currently considered the earliest potential indicators of 
disease followed by CSF tau and FDG PET, then structural MRI, prior to changes in 
clinical function. Figure 1.4 illustrates one potential model of the cascade of current 
biomarkers of Alzheimer’s disease. In addition to these well-established neuroimaging 
biomarkers, diffusion tensor imaging (DTI), functional MRI (fMRI), resting state fMRI 
(RS-fMRI), and MR spectroscopy (MRS) have all been used to further our understanding 
of AD and investigated as potentially more sensitive indicators of disease. However, as of 
yet, there are no definitive biomarkers of the disease, and as a result there continues to be 
a need to improve MRI related measurements, as this non-invasive imaging modality is 
highly cost effective and widely accessible.  MRI will be discussed in more detail in the 
following section. 
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Figure 1.4 Proposed cascade of biomarkers in Alzheimer’s disease 
One potential cascade of the biomarkers associated with Alzheimer’s disease in this figure from 
Jack et. al.70 The earliest changes are expected to be Aβ accumulation detected in CSF and PET 
imaging, followed by CSF tau and synaptic dysfunction measured using FDG-PET, brain atrophy 
and neuronal loss measured using MRI, memory loss and clinical function measured by cognitive 
assessments.[4]  
 
1.5.1 Magnetic Resonance Imaging 
Magnetic resonance imaging (MRI) is a non-invasive imaging modality without 
ionizing radiation used to produce three-dimensional anatomical images (~1 mm3 voxel 
size). The tissue in our brain is composed of approximately 80% water molecules, which 
contains protons. The MRI scanner produces a strong magnetic field and causes the 
protons within a sample to distribute between two different energy states (low energy and 
high energy).  This is known as Zeeman splitting.  There is a slight excess of protons in 
the low energy state inside the magnetic field of the MRI scanner. A radiofrequency 
                                                
[4] Adapted from The Lancet Neurology, 9 (2010), C. R. Jack, et. al., Hypothetical model 
of dynamicbiomarkers of the Alzheimer's pathological cascade, 119-139, © 2016, with 
permission from Elsevier 
 
 
15 
pulse is then applied to the sample, causing an excitation of the sample whereby some 
protons are elevated to the high-energy state and are brought into phase coherence. After 
the pulse, protons return to their baseline (equilibrium) energy level distribution within 
the magnetic field of the MRI. There are two processes that contribute to the relaxation of 
the protons back to equilibrium.  First, T1 relaxation is the process by which the protons 
lose energy to the sample and the high energy spins return to the low energy state. 
Second, T2 relaxation is the process that describes the loss of phase coherence of the 
spins after the excitation pulse. The loss of energy and phase coherence of the sample is 
recorded as spatially localized signals using a radiofrequency (RF) coil tuned to the 
frequency of protons in the magnetic field. The use of magnetic field gradients to encode 
spatial information in combination with signal excitation is used to produce detailed 
anatomic images. 
The relative signal intensities of tissues in MR image is determined by 1) the 
radiofrequency pulse used, 2) the intrinsic T1 and T2 relaxation time constants of the 
tissue, and 3) the proton density of the tissues. Therefore, depending on the scanning 
protocols, the brain gray matter, white matter and CSF can be differentiated based on 
voxel intensity. Proton density (PD), T1-weighted and T2-weighted methods are typically 
used for structural imaging. Figure 1.5 shows the gray matter, white matter, and CSF in 
T1-weighted and T2-weighted images. In T1-weighted MR images, the intensity 
distributions of the tissues in the normal adult brain has the highest intensity in white 
matter, medium intensity in gray matter, while CSF has the lowest intensity. Gray matter 
contains more cell bodies including neurons and glial cells than white matter, which 
primarily consists of nerve fibers (myelinated axons), along with supporting glial cells. In 
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T1-wighted images, the CSF as well as dense bone and air become dark (void of signal). 
Fat tissue like lipids in the myelinated white matter appears bright. Therefore, this 
anatomical image can provide contrast between gray matter and white matter as well as 
between subcortical gray matter and white matter. In addition, it offers good contrast 
between neocortex and white matter. While in T2-weighted images, CSF appears bright 
(high-intensity), while fat such as lipid in white matter shows dark (low-intensity). T2-
weighted images provide good contrast between CSF (high-intensity) and brain tissue 
(low-intensity) and are more sensitive to white matter disease due to the hyper-intensity 
of tissue with increased water content. Recently, brain volumetric measurements from T1-
weighted MR images of the brain including gray matter, hippocampus, amygdala, and the 
brain ventricle have been investigated in subjects with AD and healthy subjects using 
semi-automated or automated segmentation techniques.71-74 Hippocampus volume 
reduction75-77 and enlargement of ventricle volume63 are the most common neuroimaging 
biomarkers in subjects with MCI and AD.78 The use of such MRI biomarker could aid in 
the diagnosis, treatment planning, and treatment monitoring of people with AD. 
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Figure 1.5 Gray matter, white matter, and CSF in T1/T2 weighted images 
Gray matter, white matter and CSF in T1-weighted and T2-weighted images are shown for one 
healthy subject. Images are adopted from ADNI (Alzheimer Disease Neuroimaging Initiative) 
database.  
 
1.5.2 Positron Emission Tomography 
Positron emission tomography (PET) is a radiotracer imaging technique with tracer 
compounds labeled by positron-emitting radionuclides that are injected into the subject. 
After injection of a tracer, the subject is placed into a PET scanner within the field of 
view (FOV) of a number of detectors. The radionuclide in the radiotracer decays resulting 
in positron emission. The released positron interacts with an electron and produces two 
photons that are released in opposite directions (separated by 180 degrees). These 
photons are detected and localized by the detector array surrounding the subject. These 
events can be stored in arrays corresponding to projections through the subjectand 
reconstructed to form an image using standard tomographic techniques.79,80 The resulting 
images show the tracer distribution throughout the body and can be used to track 
biochemical and physiological processes in the subject.  
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In AD there are two radiotracers have been most commonly investigated. 
18Fluorodeoxyglucose provides functional information based on measuring cerebral 
glucose metabolic rate (CMRglc) and is an indicator of neuronal activity in AD subjects. 
Reductions of CMRglc may occur early in AD, are associated with disease progression, 
and could be used as a predictor of histo-pathological diagnosis.56 Previous studies have 
shown that the CMRglc is decreased in AD subjects, particularly in the medial temporal 
lobe, posterior cingulate, and temporo-parietal areas.81-83 The accuracy of distinguishing 
AD from healthy subjects was shown to be 98% with 99% sensitivity and 98% specificity 
based on CMRglc abnormalities in several ROI including parietotemporal and posterior 
cingulate cortices.84 In addition, subjects with MCI can be classified from healthy people 
with 79% accuracy, 68% sensitivity and 100% specificity.85 
Another more recent molecular PET imaging tracer is 11C-Pittsburgh Compound B 
(11C-PIB),86 which binds to amyloid plaques. PIB retention reveals the presence of 
amyloid in brain regions of AD subjects. A previous study compared the PIB-PET 
retention in several ROIs, but the highest accuracy of 96% to discriminate between AD 
subjects and healthy subjects was found in the posterior cingulate, with 94% sensitivity 
and 100% specificity. The accuracy of diagnostic classification between MCI and AD 
groups was 70% with 94% sensitivity and 62% specificity using retention in the middle 
frontal gyrus.87 Over the past five years, tau ligands have also been developed for PET 
imaging and are now being intensively studied.88,89 One limitation of PET scans is that 
the typical effective radiation dose of FDG is about 7 mSv and the effective radiation 
dose with PET-CT is 5 to 18 mSv90 while the natural background radiation dose is 3 
mSv. In addition, production of FDG requires a cyclotron and FDG has a short half-life 
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(110 min). Therefore, delivery from the manufacturer and completion of the scan must 
occur very rapidly. However, a PET scan could aid and improve diagnostic accuracy and 
therefore the potential benefits are often more important than the radiation risk. 
 
1.5.3 Resting State Functional Magnetic Resonance Imaging 
Functional magnetic resonance imaging (fMRI) is a non-invasive functional 
neuroimaging technique that uses the MRI to infer brain activity using blood oxygen 
level dependent (BOLD) contrast.  In particular, blood cells containing oxygenated 
hemoglobin are diamagnetic and don’t distort the magnetic field, while blood cells 
containing deoxygenated hemoglobin are paramagnetic and produce a localized magnetic 
field distortion.  The signal intensity in BOLD images is related to the ratio of 
oxygenated to de-oxygenated hemoglobin levels in the blood, which is also affected by 
changes in local blood flow and volume. T2*-weighted imaging is typically the most 
sensitive to changes in BOLD signal. When local brain activity increases, the local blood 
flow increases to meet increased glucose demands. However typically there is an 
oversupply of oxygenated blood for the required oxygen demands. Therefore, the relative 
amount of de-oxygenated hemoglobin decreases and the intensity of the BOLD weighted 
image increases. The spatial resolution of fMRI varies from 1 to 6 millimetres with a 1-5 
second (between volumes) temporal resolution. While other techniques including 
electroencephalography (EEG) or magnetoencephalography (MEG) have a higher 
temporal resolution (ms), they suffer from poorer spatial resolution. 
Spontaneous low frequency fluctuations (<0.1 HZ) in the BOLD signal have been the 
subject of intense study in the last five years.  Initial studies with an overt finger-tapping 
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task and without performing an explicit task or thought (resting state) were performed by 
Biswal et.al. in 1995.91 Biswal and colleagues compared the functional connectivity 
derived from a finger-tapping task in sensorimotor cortex to the same subjects during a 
resting state. They showed low frequency signal in the resting brain was highly correlated 
with the task activation map. Functional connectivity is expressed as the association 
between the neuronal activation of anatomically separated brain regions.92 Analysis of 
resting state fMRI data reveals brain networks.  The organized functional architecture can 
be categorized into two groups, 1) model dependent and 2) data driven methods. In the 
model based method, some anatomical/structural ROIs that are called seeds are selected. 
Correlation metrics are used to make a functional connectivity map by determining 
whether other regions are functionally related and connected to these seed regions.93 
These metrics include cross correlation analysis94 and coherence analysis.95 The data 
driven methods are divided into two categories; decomposition methods including 
independent component analysis (ICA),96 principle component analysis (PCA),97,98 and 
clustering algorithms.99 
The limitation of seed based methods is that hypothesis driven seeds must be 
selected. Independent component analysis or clustering methods are limited by the 
definition of the optimal number of independent components (IC) or clusters. However, 
some metrics are used to predict the "goodness-of-fit" to determine the optimal number 
of (IC) or clusters. Generally, a low number of components (20-30) are sufficient for 
identifying networks and avoiding the redundancy that occurs with increasing numbers of 
components.100 
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Previous studies100 have shown that several networks of functionally related brain 
regions are active during the resting state, and are called resting state networks (RSNs).  
The ICA method can be used to detect these RSNs. The ten most common RSNs are: 1) 
left executive control network, 2) right executive control network, 3) auditory network, 4) 
visual medial network, 5) visual occipital network, 6) visual lateral network, 7) salience 
network, 8) default mode network, 9) sensorimotor network and the 10) cerebellar 
network. The three visual networks are associated with cognition–language (orthography) 
and cognition–space functions. The executive network includes several medial frontal 
regions, the anterior cingulate and the paracingulate, and is associated with several 
cognition, action, emotion, and perception tasks. The cerebellar network includes the 
cerebellum and plays role in motor control and some cognitive domains. The auditory 
network covers the superior temporal cortices and is associated with speech processing, 
language processing, and perception–audition functions. The salience network includes 
frontoparietal areas and is associated with cognition and language paradigms. The 
sensorimotor network mainly consists of the primary motor area and somatosensory 
cortex and has functions in bimanual action tasks and the control of sequences of 
movements. The default mode network mostly consists of medial, anterior, lateral lobes, 
medial prefrontal cortex, and the posterior cingulate cortex (PCC). It is associated with 
emotion, episodic memory, thoughts and judgments.100 Previous studies have identified 
decreased activity in the default mode network mainly in the hippocampus in AD 
compared to healthy elderly groups and have suggested that it could be used as a clinical 
marker of AD.101,102 A cross-sectional study showed that the activity of the default mode 
network may actually increase at the early stages of MCI but is decreased in the later 
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stages of MCI, similar to the decrease shown in AD patients.103 These changes could be 
related to underlying structural changes that consequently affect the communication 
between structurally connected regions and could directly relate to the common 
symptoms associated with MCI, AD and their various stages of severity. 
In summary, neuroimaging is a promising method for the early detection of AD. 
There are multiple brain imaging techniques that can be used to detect abnormalities or 
changes in the brain, including PET, MRI, and RS-fMRI scans.  These methods in 
combination with advanced registration, segmentation, and the use of classifiers could 
significantly increase the sensitivity and specificity of AD detection.  The studies detailed 
in this thesis illustrate the basic theory of registration, segmentation and the use of 
classifiers that can be applied to brain imaging.  Specific details of these methods will be 
provided in the following sections. 
1.6 Registration 
Registration is the process of alignment a target (moving) image MX with a source 
(fixed) image FX by finding the spatial mapping between the two images. The registration 
can be applied on image feature space including pixel (voxel) intensities from the entire 
image or some points (landmarks) within the images.104 Registration algorithms involve 
several components including geometric transformation, similarity metrics, and 
optimization processes. The transform component TX represents the spatial mapping of 
points from the fixed image space to points in the moving image space.  A similarity 
metric component S (FX, MX ∘ TX) provides a measure of the goodness that the fixed 
image is aligned to the transformed moving image. An optimizer component is an 
algorithm used to find the transformation parameters that maximize the matching 
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criterion.  Registration methods can be classified into rigid (only rotation and translation), 
affine (rotation, translation, scaling, and shearing), and non-rigid registration with more 
degrees of freedom (parameters) based on the dimensionality of the transformation 
matrix.105 Often, rigid or affine registration methods are used as a pre-processing step 
before non-rigid registration to align two images.  
The similarity metric evaluates the goodness value of an objective function and is 
passed to the optimizer algorithm. Therefore selection of an appropriate metric is highly 
dependent on the registration application. There are different similarity metrics including 
mean squared error (MSE), normalized mean score error (NMSE), normalized correlation 
coefficient (NCC), and the normalized mutual information (NMI). The mean square 
error105 (MSE) is the simplest and most straightforward similarity metric and is defined 
by Equation 1.1 below. 
 
MSE 𝐹,𝑀 =      !
!
𝐹 𝑥,𝑦 −𝑀(𝑥,𝑦) !!!      [1.1] 
F (x, y), and M (x, y) are the intensities of pixel in the fixed image (F) and moving 
image (M) at location x, y. The optimal value of the metric is zero and poor registrations 
produce large values of the metric. This metric relies on the assumption that the intensity 
representing the same homologous point is the same in both images and therefore is only 
suited for two images with the same intensity distributions, i.e. for images from the same 
modality. In order to overcome this problem, one may use a normalized version of the 
metric as shown in Equation [1.2]. 
NMSE 𝐹,𝑀 =
1
𝑁
𝐹 𝑥,𝑦 − 𝐹
𝐹 − 𝐹 !
−
𝑀 𝑥,𝑦 −𝑀
𝑀 −𝑀 !
!
                                                                        [1.2]
!!
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F (x, y), and M (x, y) are the intensities of the pixel in the fixed image (F) and 
moving image (M) at location x, y. 𝐹 and 𝑀 are the mean intensity value in the fixed and 
moving images. 𝐹 − 𝐹 ! and 𝑀 −𝑀 !  are the L2-normfor the intensity scale 
normalization.L2-norm is also known as the Euclidean norm and L2-norm of vector 
X=(x1, x2,…, xn) is given by Equation [1.3]: 
𝑋! = 𝑥! !
!
!!!
                                                                                                                                                                                                                                  [1.3]         
Another normalized metric is the normalized correlation coefficient106 (NCC) shown 
in Equation [1.4]. 
𝐍CC 𝐹,𝑀 =   
1
𝑁
𝐹 𝑥,𝑦 − 𝐹 𝑀 𝑥,𝑦 −𝑀
𝜎!𝜎!!!
                                                                                                          [1.4]   
𝜎! and  𝜎! are the standard deviations of the intensities in the fixed and moving images 
and have an ideal value of 1. This metric computes the correlation between pixels in the 
fixed image and pixels in the moving image.  The correlation is normalized by the square 
rooted autocorrelations of both the fixed and moving images. The metric is invariant to 
linear differences between intensity distributions and is therefore appropriate for a single 
modal registration and for multi-modality registration. 
Equation [1.5] provides the definition of the normalized mutual information (NMI)107 
function: 
NMI 𝐹,𝑀 =   
𝐻 𝐹 + 𝐻(𝑀)
𝐻(𝐹,𝑀)                                                                                                                                                                                                       [1.5] 
The Mutual Information (MI) measure computes the mutual information between 
two images and is more general. MI is a measure of how much information one random 
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variable (image intensity in one image) tells about another random variable (image 
intensity in the other image). This corresponds to measuring the dependency of the 
probability distribution function (PDF) of the intensities of the fixed and moving images 
without having to specify the actual form of the dependency. Normalized Mutual 
Information is appropriate for multi-modality registration.  
 
1.6.1 Registration Validation 
To evaluate the effectiveness of a registration method, an anatomically homologous 
pair of landmarks is identified and target registration error (TRE)108 is measured and 
denoted by Equation [1.6]. 
                                                    TRE =    𝑇 𝑥! − 𝑥!
! + 𝑇 𝑦! − 𝑦!
!                                                                                          [1.6]       
This metric measures the Euclidean distance between the location of the transformed 
moving landmark and its homologous fixed landmark. A perfect registration has an ideal 
value of zero. In practice, we manually identify multiple anatomically homologous 
landmark pairs, and calculate TRE for each pair. The final TRE value is measured by 
taking their mean.   
In practice, three measures of volume overlap and two measures of overlap error can 
be used to evaluate the overlap of registered images.  
The first volume overlap measurement is called the target overlap (TO).109  This 
measure computes the intersection between two regions r in a transformed moving image 
(S) and a fixed image (F) divided by the volume of the region in the fixed image denoted 
by Equation [1.7]. 
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𝑇𝑂 =
𝑆! ∩ 𝑇!
𝑇!
                                                                                                                                                                                                                                                          [1.7] 
The second volume overlap measurement is called the mean overlap (MO).109 It is 
the intersection divided by the mean volume of the two or multiple regions and is denoted 
by Equation [1.8]. 
𝑀𝑜 = 2
∑! 𝑆! ∩ 𝑇!
∑! 𝑆! + 𝑇!
                                                                                                                                                                                                                          [1.8] 
The third volume overlap measurement is called the union overlap (UO).109 It is the 
intersection divided by the union of the two or multiple regions as denoted by Equation 
[1.9]. 
𝑈𝑂 =
∑! 𝑆! ∩ 𝑇!
∑! 𝑆! ∪ 𝑇!
                                                                                                                                                                                                                                              [1.9] 
The false negative error109 is a measurement of how much of the region is incorrectly 
labeled. It is computed as the volume of a fixed region outside the corresponding 
transformed moving region divided by the volume of the fixed region and denoted by 
Equation [1.10]. 
𝐹𝑁 =
∑! 𝑇!\𝑆!
∑! 𝑇!
                                                                                                                                                                                                                                                [1.10] 
Where 𝑇!\𝑆! shows the set of voxels in the fixed region but not in the transformed 
moving region. 
The false positive error109 is the measurement of how much of the volume outside a 
region is incorrectly labeled as inside region. It is computed as the volume of a 
transformed moving region outside the corresponding fixed region divided by the volume 
of the transformed moving region and is denoted by Equation [1.11]. 
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𝐹𝑃 =
∑! 𝑆!\𝑇!
∑! 𝑆!
                                                                                                                                                                                                                                                [1.11] 
 
 
1.7 Segmentation 
Image segmentation is the process of the identification of image pixels within regions 
or categories that correspond to different objects or parts of an object.110 In 2D/3D/4D 
medical images, these segments often relate to different tissues, organs, or other relevant 
structures. Low contrast, noise, and other imaging artefacts can make medical image 
segmentation difficult. Imaging modalities including MRI generate three dimensional 
image volumes with high resolution and a large number of image slices making manual 
examination extremely time consuming. However, automated or semi-automated image 
segmentation techniques can overcome this problem and have been adapted specifically 
for medical image analysis. In addition, image segmentation methods are required in 
clinical applications to assist the observer in generating quantitative measurements and 
may provide support in diagnosis and response to treatment planning.  Segmentation 
algorithms can be divided into low level and model based categories. Low level includes 
boundary-based, region-based and pixel-based segmentation methods. Model based 
methods incorporate high-level image features including boundary smoothness, shape, 
and appearance. Edge based or boundary methods are the most common approaches to 
find discontinuities in gray level images using edge detectors. Edges are the boundary 
between two regions. All the edge detection operators are grouped into first order and 
second order derivatives.  
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1.7.1 Region-Based Method 
Region-based techniques partition an image into regions. Region growing is the 
simplest region-based method,111 which groups pixels or sub regions into larger regions 
based on predefined criteria. A set of seeds (pixels) is selected in the image and a 
similarity criterion (e.g. intensity, color, texture) is defined. Then the region grows when 
the neighbouring pixels have a similar value and the region growing stops when no more 
pixels meet the criteria. Region growing algorithms differ in the criteria used to 
determine whether a pixel is included in the region or not. A major limitation of this 
technique is that regions of interest can have very similar intensity. If two anatomical 
structures share a boundary and the same intensity distribution, the growing region will 
’leak’ into undesirable regions. If the regions have uniform intensities and clear 
boundaries, region-growing methods can be quick and effective for many segmentation 
problems.  
 
1.7.2 Pixel-Based Method 
Thresholding is the simplest method for pixel-base segmentation112 and is used to 
identify pixel values in an Image I (x, y) based on specifying one or more values as the 
threshold value. This operation transforms an image to a binary map by changing the 
pixel values according to the threshold value. Upper and lower thresholds are two 
intensity values defined by user. If the pixel value belongs to the defined range (lower, 
upper) the intensity of the output pixel is unchanged, otherwise the intensity is changed to 
zero. The major disadvantage of this method is that it is not appropriate for complicated 
images, but if there is a good contrast between regions, it performs well.  
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1.7.3 Level Set 
The level set method implicitly represents a contour or surface by defining a level set 
function that is usually defined on the same domain as the image. This method was 
proposed by Osher and Sethian.113  The level set114-116 is considered as the set of points 
that have the same function value. For example a contour can be embedded as a zero 
level set of the higher-dimensional level set function Ψ (x, y) by Equation [1.12]: 
𝜓   𝑥,𝑦 = 0                                                                                                                                                                                                                                                                [1.12] 
and every point of the region Ω is determined by the sign of  the level set function Ψ 
by Equations [1.13, 1.14]: 
𝜓   𝑥,𝑦 > 0,                   𝑥,𝑦 ∈   Ω                                                                                                                                                                                                    [1.13] 
𝜓   𝑥,𝑦 < 0,                   𝑥,𝑦 ∉   Ω                                                                                                                                                                                                    [1.14] 
The contour at the zero level set can be evolved by updating the level set function at 
fixed coordinates through time by Equation [1.15] 
𝜕𝜓
𝜕𝑡 = 𝑉 ∇!                                                                                                                                                                                                                                                                 [1.15] 
where V is a speed function to evolve the contour throughout the image domain. The 
main advantage of the level set method is that a complex shape and topological changes 
including merging and splitting can be modeled.  
 
1.8 Classifiers 
Machine learning (ML) is a process of developing algorithms that uses input data to 
accomplish a desired task. These algorithms are trained through experience and therefore 
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their performance improves to obtain a particular outcome. This training is the learning 
part of machine learning. The selection and weighting of input data and the algorithm’s 
parameters that are modified through iterative optimization can help to improve the 
training portion. To achieve this goal, a dataset can be divided into training and testing 
sets; the training set is used to teach the algorithm to accomplish a goal and the testing set 
is used to validate the acceptability of the identified goal. Machine learning can be 
divided into supervised, unsupervised, and semi-supervised learning based on the nature 
of data labeling. The goal of supervised learning is to learn how to estimate an unknown 
data (input, output) mapping from the training set (input, output), where the output is 
labeled (e.g. an artificial neural network, or a support vector machine). In the 
unsupervised leaning, the input data is given to the learning system to infer a function to 
describe hidden patterns in the data. The inputs that are used in this leaning are unlabeled 
(e.g. principle component analysis and clustering methods). Semi-supervised learning is a 
type of supervised learning and uses a combination of both labeled data and unlabeled 
data where the labeled data is used to estimate the unlabeled data. Another category of 
machine learning is reinforcement learning that is presented with inputs, actions, and 
rewards. Its goal is to learn how to find a sequence of actions that may maximize the 
reward (e.g. robots, chess programs).117 Figure 1.6 summarizes of these types of machine 
learning. 
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Figure 1.6 Different categories of machine learning 
In supervised learning, labeled examples are available, while in unsupervised learning, labeled 
examples are not available. Semi-supervised learning combines both labeled and unlabeled 
examples to generate an appropriate function.  
 
Supervised learning is the most commonly used method in neuroimaging. The input 
data is determined by a number of image features like the number of voxels, mean 
intensity, standard deviation of intensity, and volumes of ROIs. The output data is the 
subject’s class or label (ground truth). The labels are often binary, for example patient or 
control, or improver or decliner. Here, the objective of ML methods in neuroimaging is to 
use image features to predict the subject’s label. These ML methods are also called 
classifiers. ML algorithms (classifiers) have been used previously to identify subjects 
with Alzheimer disease from healthy subjects using MRI biomarkers.118  For example, in 
one study, the classification accuracy was 76% between AD and healthy subjects and 
72% between MCI and healthy subjects using training data from 137 AD, 76 MCI and 
162 healthy subjects.118 
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1.8.1 Support Vector Machine 
The support vector machine119,120 (SVM) is one of the most powerful tools for 
supervised learning and is used in classification and regression problems. SVM 
algorithms are well known for their strong statistical theory, generalizable performance, 
and ability to handle highly dimensional data.121,122 The training data can be characterized 
as 𝑥!,𝑦! … 𝑥!,𝑦!  where 𝑥!  , 𝑖𝜖  𝑛  are multi dimensional instances (observations), 𝑦! 
are the labels of those instances, and n is the number of instances in the training set. In 
neuroimaging 𝑥!  is the feature vector characterized from each image, 𝑦! ∈    (+1,−1) is a 
label that is assigned to each subject and n is the number of subjects in the training set. 
SVM is a classification method to find the optimal separating hyperplane between the 
positive examples (labeled +1) and the negative examples (labeled -1) with the largest 
margin. The margin is defined as the distance between the hyperplane and the training 
examples (positive and negative examples) that are closest to the hyperplane. Figure 1.7 
shows this hyperplane between positive samples (red circles) and negative samples 
(green squares). 
 
 
Figure 1.7 Separation line between two classes using a support vector machine 
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Therefore, the hyperplane can be defined by the normal vector 𝑊 and intercept 𝑏 by 
Equation [1.16]: 
𝑊!𝑥 + 𝑏 = 0                                                                                                                                                                                                                                                            [1.16] 
Here, the labels 𝑦! ∈    +1,−1  corresponding to the examples 𝑥!  , 𝑖𝜖  𝑛 in the training 
set are replaced by +1, -1 according to the following rule by Equation [1.17]: 
𝑦! =
1             ∶   𝑊!𝑥! + 𝑏 > +1
−1       ∶   𝑊!𝑥! + 𝑏 < +1
                                                                                                                                                                                              [1.17] 
These two constraints can be combined into the following by Equation [1.18]: 
𝑦! 𝑊!𝑥! + 𝑏 ≥ 1                                      ∀!                                                                                                                                                                                           [1.18] 
The margin can be easily computed as the distance between the example point x and 
hyperplane based on geometry as follows by Equation [1.19]: 
Margin =   
𝑏 +𝑊!𝑥
𝑊 =
1
𝑊                                                                                                                                                                                             [1.19] 
𝑊  is the Euclidean norm of W. The problem of maximizing the margin is not easy 
because the vector norm includes a square root. Therefore, it is equivalent to minimizing 
the problem by Equation [1.20]: 
min  𝐿 𝑊 = 𝑊 !                                subject  to                                𝑦! 𝑊!𝑥! + 𝑏 ≥ 1      ∀!                                             [1.20] 
This formulation is known as the primal form and is solved using the Lagrangian 
formulation by Equation [1.21]: 
min
!,!
𝐿 𝑊, 𝑏,𝛼 =    𝑊 ! − 𝛼!𝑦!
!
!!!
𝑥!𝑊 + 𝑏 + 𝛼!
!
!!!
                                                                                              [1.21] 
The non-zero Lagrange multipliers (𝛼! > 0) are called support vectors and they 
correspond to example points that lie directly on the optimal margin. 
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When the data is not linearly separable using kernels can enable the use of support 
vector machines.  Kernel methods can be used in the Lagrangian expression of the SVM 
optimization problem by incorporating a kernel function. With this approach, the data can 
be mapped to a higher dimensional space where the data is linearly separable. There are a 
number of kernel types including linear, polynomial, Gaussian, and sigmoidal. In a real 
application, kernel methods do not guarantee optimal results and may lead to over-fitting. 
To overcome this limitation, regularization or a soft margin can be used to find a 
hyperplane by relaxing the constraints in the optimization problem. Typically the 
regularization parameter C and another parameter γ (when using a Gaussian kernel) that 
control the mapping of the original data to the higher dimensional space require 
optimization.123-125 The advantages of the SVM are that it is an accurate classifier with 
little over-fitting and is robust to noise. The disadvantage of the SVM is that its 
performance is highly dependent on parameter tuning and it is only a binary classifier.126  
Cross validation is a statistical type of validation learning algorithm that works by 
dividing data into two groups: (1) training data is used to learn a model and (2) test data 
is used to evaluate the model.127 Cross validation methods estimate the performance of a 
learned model using the test data.128 They can be used for comparison between two or 
more algorithms to find the best one.  There are a number of ways to achieve this goal. 
One of the most widely used when the sample size of the data is small is the leave-one-
out cross validation (LOOCV).129,130 Here, in each iteration, all the data (training data) 
except one single datum (test datum) is used to train the model and the model is tested on 
that test datum. This process is repeated so that each sample in the data is used as the test 
datum. LOOCV is known to suffer from over-fitting and over estimates the performance 
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of models. Another popular method is k-fold cross validation131,132 which divides the data 
set into k folds and the model is trained using k-1 folds. The model is validated using the 
k-th fold (test data). This process is repeated k times.  
1.9 Validation of classification performance 
Accuracy, sensitivity, and specificity are statistical measurements to evaluate the 
performance of a binary classification such as SVM. For example with two classes (1 and 
2), class 1 refers to a group of patients (“positive” based on the clinical conditions) and 
class 2 corresponds to a group of controls (“negative” based on the clinical condition). 
The four components are typically characterized are: 
1. True positive (TP): the number of subjects who have the positive condition 
(patient) correctly identify as class 1 (patient)  
2. False positive (FP): the number of subjects who have the negative condition 
(controls) incorrectly identify as class 1 (patient)  
3. True Negative (TN): the number of subjects who have the negative condition 
(controls) correctly identify as class 2 (controls)  
4. False negative (FN): the number of subjects who have the positive condition 
(patient) incorrectly identify as class 2 (controls)  
 
Therefore, the sensitivity, specificity, and accuracy can be defined using Equations [1.22-
1.24] below: 
Sensitivity =   
𝑇𝑃
𝑇𝑃 + 𝐹𝑁   ×  100                                                                                                                                                                                        [1.22]   
Specificity =   
𝑇𝑁
𝑇𝑁 + 𝐹𝑃   ×  100                                                                                                                                                                                            [1.23] 
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Accuracy =   
𝑇𝑃 + 𝐹𝑁
𝑇𝑃 + 𝑇𝑁 + 𝐹𝑃 + 𝐹𝑁   ×  100                                                                                                                                                  [1.24] 
 
Sensitivity is the proportion of patients that are correctly identified; specificity is the 
proportion of healthy subjects that are correctly identified. Accuracy is the percentage of 
correct classifications. The error rate= 1- accuracy, is the percentage of incorrectly 
classified subjects. 
 
1.10 Validation of segmentation techniques 
One of the most challenging issues in a clinical setting is the comparison of different 
segmentation methods. Initial evaluation is often accomplished visually by overlaying 
contours or boundaries derived from each segmentation methods on the medical images. 
To overcome drawbacks intrinsic to visual perspective, a quantitative validation is 
preferable and most approaches use a gold standard to compare different methods. A 
ground truth method can be considered a benchmark to test against, however actual 
ground truth knowledge is often not available. A physical or digital phantom can be 
constructed for which the ground truth is known, but a problem is associated with this 
approach. Composing a physical phantom is challenging because it is difficult to 
reproduce the normal and pathological anatomical variability observed in clinical data. 
Gold standards typically rely more on contours that are manually defined by clinical 
experts in the medical images of interest. This manual segmentation is performed by 
using anatomical landmarks to produce label maps (also know as a mask). Therefore, to 
assess the performance of a segmentation technique, some statistics measurements are 
used to compare a newly developed method to an existing method or gold standard. For 
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this purpose, some metrics are described below and can be divided into three groups 
including spatial overlap, distance and volumetric measures.  
 
1.10.1 Region-Based Metric 
Region based metrics compute the overlap between regions. This metric is used to 
measure the portion of spatial overlap between two mask images that were generated by 
the segmentation method (𝑟𝑒𝑔𝑖𝑜𝑛!) and a gold standard (𝑟𝑒𝑔𝑖𝑜𝑛!). 
The Dice similarity coefficient (DSC)133 is defined by Equation [1.25]: 
DSC =   
2 𝑟𝑒𝑔𝑖𝑜𝑛! ∩ 𝑟𝑒𝑔𝑖𝑜𝑛!
𝑟𝑒𝑔𝑖𝑜𝑛! + 𝑟𝑒𝑔𝑖𝑜𝑛!
                                                                                                                                                                                          [1.25] 
The Jaccard index (JI)134 is characterized as a proportion of the intersection between 
two regions over their union by Equation [1.26]: 
JI =
𝑟𝑒𝑔𝑖𝑜𝑛! ∩ 𝑟𝑒𝑔𝑖𝑜𝑛!
𝑟𝑒𝑔𝑖𝑜𝑛! ∪ 𝑟𝑒𝑔𝑖𝑜𝑛!
                                                                                                                                                                                                      [1.26] 
The Jaccard index is always larger than the Dice index but both of these metrics 
measure the same aspects and do not provide additional information. 
 
1.10.2 Distance-based metric 
This metric can measured the distance between points in 𝑟𝑒𝑔𝑖𝑜𝑛! and 𝑟𝑒𝑔𝑖𝑜𝑛! . 
Mean absolute distance (MAD)135,136 is defined by Equation [1.27]: 
MAD =   
1
𝑁 𝑑(𝑃!,𝑃!)
!
!!!
                                                                                                                                                                                                                [1.27] 
where 𝑃! is the set of points in 𝑟𝑒𝑔𝑖𝑜𝑛! and 𝑃! is the set of points in 𝑟𝑒𝑔𝑖𝑜𝑛!. N is 
the number of points and this distance is based on the Euclidean distance in mm.  
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The Hausdorff distance137 is the measurement of the error between two surfaces. It 
computes the maximum distance of a set point in region A to the nearest point of region 
B. Therefore, this distance can be used to determine the degree of similarity between two 
regions that are superimposed on one another and denoted by Equation [1.28]. 
ℎ 𝐴,𝐵 = max
!  ∈!
min
!  ∈!
𝑑 𝑎, 𝑏                                                                                                                                                                                           [1.28] 
 
1.10.3 Volume based metric 
The percentage volume difference (VD) is defined as the ratio of the absolute 
difference between the segmented volume 𝑉! and the gold standard volume 𝑉!  by 
Equation [1.29]: 
VD =   
𝑉! − 𝑉!
𝑉!
  ×100                                                                                                                                                                                                                          [1.29] 
 
1.10.4 Variability 
Human expert operators have often been used for gold standard segmentations and 
many segmentation methods use initialization or manual intervention. These are 
associated with high intra-observer and inter-observer variability. Therefore, the 
variability can be measured by the intra-class correlation coefficient (ICC),138,139 Bland-
Altman plot,140 and the coefficient of variation.141  These metrics are used to describe the 
effect of accuracy between and within operators and segmentation methods.  
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1.11 Thesis Overview 
The preclinical or pre-symptomatic stage of AD is associated with pathological 
changes that begin 10-15 years before synaptic or neuronal loss result in cognitive 
decline and dementia. New disease modifying drugs are urgently needed to intervene at 
the pre-symptomatic stage in the disease process to prevent brain damage and subsequent 
cognitive decline and dementia. Currently, AD is diagnosed base on the results of a 
clinical examination and cognitive testing.  But such a diagnosis occurs too late in the 
disease process and is subject to error because a definitive biomarker does not exist.142 A 
diagnosis based on clinical examination and cognitive testing cannot detect pre-
symptomatic AD and cannot accurately measure the rate of disease progression. There is 
an urgent need to develop biomarkers that can definitively identify early Alzheimer’s 
disease so that new potentially disease modifying drugs can be tested in the appropriate 
people. 
It is challenging to develop biomarkers for presymptomatic AD because early 
changes in the brain are subtle. The ideal biomarker should reveal AD pathology, be 
reliable, be easy to measure, and be relatively inexpensive.143 Imaging methods including 
anatomical MRI, PET, and functional MRI, which can assess regional/global structural 
and functional impairment have the potential, particularly when used in combination, to 
identify pathological changes associated with AD.  
The overall objective of this thesis is to develop and test novel structural and 
functional biomarkers of Alzheimer’s disease to improve AD diagnosis and treatment 
monitoring.  Chapter 1 provides the necessary introductory material including an 
overview of AD, MCI, the neuropathology of AD, the clinical diagnosis of AD, a review 
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of current biomarkers, and background related to image registration and segmentation 
theories.  The thesis contains three independent chapters or studies: 
 Chapter 2 describes a new approach to the segmentation of the medial temporal 
lobe (mainly hippocampus) from T1-weighted images in healthy, MCI and AD subjects 
taking part in a longitudinal natural history study (2 years follow-up). The goal of this 
work was to develop a reliable, and fully automated approach to quantify MTL atrophy 
using MRI. The novel segmentation approach presented here combined a multiple atlas-
based registration method to define the tissue region of interest, a level set algorithm to 
refine the shape of the medial temporal lobe, and registration of baseline images to follow 
up images to increase measurement precision. We hypothesized that the change in MTL 
(ΔMTL) volume would be robustly quantified by this fully automated segmentation 
method, and would be a sensitive marker of AD progression.  
Chapter 3 describes and provides a cross sectional comparison of a new 
biomarker of brain activity derived from resting state fMRI in healthy and AD subjects. 
We also examine the association of this new metric to hypometabolism measured by 
FDG-PET in the same cohort of subjects. Here, we defined a novel metric of brain 
activity based on a first-order texture feature defined as the standard deviation of the 
magnitude of the BOLD fluctuation. The purpose of this study was to determine whether 
this new metric could be used to accurately differentiate healthy individuals from people 
with mild Alzheimer disease.  The hypothesis was that the fluctuation of the magnitude 
of the BOLD signal as a function of time is related to neuronal activity and therefore will 
also correlate with FDG-PET measures of glucose metabolism. The goal was to 
demonstrate the efficacy of this new biomarker of Alzheimer’s disease based on the 
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fluctuation of the magnitude of the RS-fMRI signal. 
Chapter 4 closely examines a group of subjects with MCI to determine whether gait 
and cognitive measures can predict or are associated with medial temporal lobe atrophy 
incorporating principle component analysis (PCA) and the SVM classifier.  Medial 
temporal lobe atrophy over 18 months was evaluated using the novel method developed 
in Chapter 2. The purpose of this study was to determine which combination of 
biomarkers could best predict hippocampal atrophy over 18 months in people with MCI. 
We hypothesized that the combination neuropsychological and gait measurements would 
provide the best predictors of hippocampal atrophy. 
Finally, in Chapter 5, we provide a summary of the findings of the thesis, a 
discussion of the limitations of the work, and suggestions for future development.  
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 CHAPTER 2: Automated Algorithm to Measure Changes in 
Medial Temporal Lobe Volume in Alzheimer Disease 
 
The work presented in this chapter has been previously published in Journal of 
Neuroscience Methods as indicated below, and is reproduced here with permission. 
 
Samaneh Kazemifar, John J. Drozd, Nagalingam Rajakumar, Michael J. Borrie and 
Robert Bartha. 
 
“Automated Algorithm to Measure Changes in Medial Temporal Lobe Volume in 
Alzheimer Disease” J Neurosci Methods. 2014 Apr 30; 227: 35-46 
 
2.1 Introduction 
Alzheimer disease (AD) is the most common form of neurodegenerative dementia1 
and progressively causes metabolic and structural changes in the brain that lead to 
symptoms of cognitive decline. In 2006, approximately 14.7% of people over the age of 
85 years were living with AD worldwide. By 2050, the worldwide prevalence of AD is 
projected to quadruple compared to 2006 levels.2 The current diagnosis of AD is made 
clinically incorporating neuropsychological and neuroimaging assessments. The clinical 
progression of AD can be measured by cognitive assessments, most commonly the Mini-
Mental-State Examination3 (MMSE), the Alzheimer Disease Assessment Scale-cognitive 
subscale (ADAS-cog)4 and more recently the Montreal Cognitive Assessment (MoCA).5 
However, these assessments have only moderate sensitivity to disease progression,4,6 
particularly in the early stages of the disease. Therefore, numerous non-invasive imaging 
techniques7-9 are being developed as potential quantitative biomarkers for the detection 
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and monitoring of small structural,10,11 metabolic,12-15 and functional16 changes during the 
early stages of the disease. In addition, the development of amyloid imaging techniques 
using positron emission tomography (PET) now provides the ability to measure fibrillar 
amyloid accumulation in the brain.17-19 These imaging tools could increase diagnostic 
accuracy and allow monitoring of disease progression and response to treatment.10,20,21 
 Magnetic resonance imaging (MRI) is used to visualize anatomical changes in the 
brain with high resolution and is therefore considered the preferred neuroimaging method 
for early detection of AD.22 Progression of AD23-26 is often associated with increased 
ventricle volume10 or atrophy of the medial temporal lobe (MTL) including the 
hippocampus.23-25,27 Although the hippocampus is considered one of the first brain 
structures affected by AD, accurate quantification of hippocampal atrophy is difficult 
because the structure has an inhomogeneous texture with poorly defined boundaries. 
Manual segmentation of the hippocampus on MRI is the gold standard 28 but is time-
consuming, subjective, and has high variability.29 In fact, only recently have attempts 
been made to standardize the definition of the hippocampus for volumetric 
measurements.30 
Several studies have proposed atlas-based segmentation techniques to find the 
optimal mappings between brain MRI and an atlas image using landmarks31-33 or 
intensities.34-39 In addition, van der Lijn et. al.40 combined atlas-based segmentation with 
graph cuts41,42 to define the hippocampus. Incorporating corresponding landmarks can 
also help to compute geometric transformations rather than relying on intensity-based 
registration. For example, an atlas-based registration method was applied by Wang et. 
al.43 to segment the hippocampus; however, this method required the manual placement 
 
 
55 
of a large number of landmarks in each scan. More recently, atlas-based registration has 
been proposed for the detection of pathological changes in addition to the segmentation 
of structures.44 Registration is treated as an optimization problem to find the spatial 
mapping between two images. For example, to segment the hippocampus and amygdala 
in images obtained from the ADNI dataset, Chupin et. al.37 registered images to a 
probabilistic atlas with image deformation performed by minimization of an energy 
function.45In general, providing an accurate segmentation of a structure using atlas-based 
registration is important; however, the accuracy of the segmentation is heavily dependent 
on the atlas. A single atlas cannot represent a whole population, particularly in datasets 
with large variation and may lead to biased results. Therefore, the performance of atlas-
based segmentation methods can often be improved using multi-atlas propagation.46-48 
A number of other methods have also been developed and applied to the 
segmentation of the hippocampus. Barnes et. al.49 developed a semi-automated 
segmentation method to measure hippocampal volume changes by calculating the 
boundary shift integral (BSI)50 in longitudinal MR images. Rusinek et. al.51 applied the 
BSI to calculate the rate of MTL atrophy. Wolz et. al.39 combined a multi-atlas 
registration with an intensity refinement model40 to segment the hippocampus.  This 
learning embedding for atlas propagation (LEAP) method was demonstrated by using 
images obtained from the ADNI database.39 Coupe et. al.38 proposed a novel patch-based 
method for hippocampus and ventricle segmentation that incorporated nonlocal means 
label fusion.52 Fischl et. al.53,54 have also proposed an automated tool (FreeSurfer) for 
segmentation of 37 neuroanatomical structures in the brain on MRI that includes 18 
labels of subcortical structures. In this approach, a probabilistic atlas image is generated 
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from a training set of 41 manually labeled brains. For each image to be segmented, the 
probability that a pixel belongs to a specific structure (label class) is computed. 
Preprocessing steps included an affine registration to Talairach space, intensity 
normalization, skull stripping, and non-linear alignment to the Talairach atlas.53,54 An 
initial segmentation is generated by assigning each pixel to the class for which the 
probability is greatest. Given this segmentation, a neighborhood function is used to 
recompute the class probabilities. The data set is then resegmented based on this new set 
of class probabilities. This process is repeated until the segmentation does not change. 
FreeSurfer is a fully automated segmentation pipeline.53,54 Similarly, Shen et. al.55 used a 
surface model for segmentation of the hippocampus. This model integrated rigid 
geometric alignment with shape variation as prior knowledge, but required manual 
placement of landmarks on the boundaries. The prior knowledge increased the accuracy 
of the boundaries and maintained the appropriate hippocampus shape, but manual 
placement of points within an individual MR image was needed. 
Existing methods of hippocampal segmentation mostly require manual intervention 
at some point in the measurement to achieve accurate results.32,43,56 However, in applying 
such methods to the monitoring of Alzheimer’s disease progression, we postulate that 
segmentation accuracy is less important than sensitivity to change. Automation may be a 
more highly desirable feature because it increases reproducibility and aids in analyzing 
large datasets in a timely manner. Automated measurements of large volumes such as 
frontal, parietal, temporal, and occipital lobes as well as cerebellum have been 
successfully demonstrated by Andreasen et. al.57 In addition, subcortical structures such 
as the thalamus, caudate nucleus, putamen and globus pallidus have also been measured58 
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using deformable shape models based on automated or semi automated image 
segmentation algorithms.59 By formulating a shape-intensity model in terms of a level set 
function60 it is possible to segment images with poor contrast and missing boundaries. 
Level sets are a type of geometric deformable model.61 Intensity-based techniques are 
difficult to apply to the segmentation of the hippocampus because signal intensity varies 
and boundaries are ill-defined. Deformable models can be used to extract boundaries 
from objects with low contrast and indistinct edges. In this study, a geometric deformable 
model (level set algorithm)62 was chosen that couldautomatically handle multiple objects 
or an object with unknown topology and sharp corners. The Fast Marching segmentation 
method is a type of level set method that can follow objects with topology changes when 
an object splits in two, develops holes, or the reverse of these operations. This method 
may offer an advantage when segmenting structures with low contrast boundaries such as 
the hippocampus. 
Therefore, the goal of the present work was to develop a robust, reliable, and fully 
automated approach to quantify MTL atrophy using MRI.  The novel segmentation 
approach presented here combined a multiple atlas-based registration method to define 
the tissue region of interest, a level set algorithm to refine the shape of the medial 
temporal lobe, and registration of baseline images to follow up images to increase 
measurement precision. The method was tested by comparing atrophy between a group of 
normal elderly controls (NEC), subjects with mild cognitive impairment (MCI), and 
subjects with AD. We hypothesized that the change in MTL (ΔMTL) volume would be 
robustly quantified by this fully automated segmentation method, and would be a 
sensitive marker of Alzheimer disease progression. We selected 24 months as the 
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longitudinal interval, as this interval has been previously used for measuring disease 
progression in AD.63 
 
2.2 Methods 
The automated segmentation approach developed in this study represents an 
expedient atrophy change in tissue (EXACT) measurement of the brain.  Briefly, EXACT 
begins with the use of the expectation maximization (EM) algorithm to remove the skull 
and non-brain tissue from each image,64 followed by a multiple atlas-based registration to 
identify the MTL volume of interest in a subject’s baseline image, and a Fast Marching 
algorithm62 (a type of level set algorithm) to refine the boundary of the MTL using image 
features such as the gradient.  The definition of the region of interest does not correspond 
to a single anatomical structure, but instead is guided by anatomical structures and 
refined using clearly identifiable tissue boundaries observed in T1-weighted images. In 
contrast, trying to find the boundaries of the hippocampus, a structure with low contrast 
compared to surrounding tissue, is difficult.45,65 In addition, inclusion of other structures 
within and beyond the hippocampus may provide increased sensitive to early AD 
pathology.66 Skull stripping and removal of non-brain tissue is repeated in the subject’s 
follow-up images. Then, baseline images are registered to skull stripped follow-up 
images. Following registration, the transformation field is used to map the MTL volume 
from the baseline image to the follow-up image.  The measured volume change in the 
MTL is the difference between the baseline and follow-up volume. A schematic 
representation of the entire automated segmentation procedure is provided in Figure 2.1.   
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Figure 2.1 Block diagram of the EXACT segmentation algorithm. 
 
The EM segmentation is a model-based classification method that uses a Bayesian 
classifier.67 The EM segmentation algorithm classifies the brain image into cerebrospinal 
fluid (CSF), grey matter (GM) and white matter (WM) according to a probability 
distribution and the pixel intensity histogram.68 It was chosen as a pre-processing step to 
extract the whole brain. Then the whole brain gray scale images of the atlas, baseline, and 
follow-up images were used in the registration step. The EM module from 3Dslicer69-71 
(http://www.slicer.org) was used in this study. 3DSlicer is open-source software and 
based on the VTK (Visualization Toolkit: http://www.vtk.org) and ITK (Insight 
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Segmentation and Registration Toolkit: htpp://www.itk.org) libraries. Although the EM 
segmentation method within 3Dslicer is one example of a skull stripping method, others 
could also be used. This tool is accessible to the research community and easy to use. We 
chose this method of skull stripping because it is automated and does not require 
parameter optimization. Other available methods (e.g. BET (Brain Extraction Tool) of 
FSL (Functional Magnetic Resonance Imaging of the Brain Software Library))72 require 
manual interaction to optimize parameters in some subjects if neck and non-brain 
structures remain. 
The EXACT method requires the rough outline of the MTL region (using a bounding 
box) a priori in each atlas by an expert.  This step is performed only once. Eight atlases 
were created using subject images from the Alzheimer’s Disease Neuroimaging Initiative 
(ADNI) database. These datasets were chosen visually because images had no visible 
rotation and medial temporal lobe atrophy spanned the range normally encountered in the 
brain in normal elderly controls (N= 3), subjects with MCI (N= 2) and subjects with AD 
(N= 3). The volume of interest (VOI) does not correspond to a specific anatomical 
structure. Rather the location is guided by the anatomical structure of interest but it is 
defined by clearly identifiable tissue boundaries that are observed in T1-weighted images. 
The purpose of the registration step is simply to establish a bounding box around the 
MTL region that contains the hippocampus. Then, subsequently a Fast Marching method 
is used to identify a gray matter VOI. Accurate segmentation of the hippocampus was not 
the goal. Rather the goal is definition of a VOI with clearly defined boundaries. In this 
way, tracking atrophy over time is more precise.  
To quantify ΔMTL volume between two time points (e.g. a baseline and follow-up 
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image) several steps were developed in ITK73,74 (Insight Segmentation and Registration 
Toolkit: htpp://www.itk.org). First the skull was removed in all eight atlases, as well as in 
the baseline and follow-up images using the EM segmentation algorithm. Then, the atlas 
that most closely matched the baseline image was selected by registering each atlas to the 
baseline image and choosing the atlas that maximized mutual information (MMI)75 
within the local MTL region. The optimum atlas image was then aligned to the baseline 
brain image. The alignment was performed using affine transformations and the Demon's 
registration method.76 The bounding box encompassing the MTL region defined within 
the optimum atlas image was propagated into the baseline image using the deformation 
matrix. A Fast Marching algorithm74 was then applied to refine the shape and smooth the 
boundary of the MTL VOI. An initialization mask around the region of interest was 
delineated. A single seed point was initiated inside the region of interest that was 
propagated outwards until it reached the desired boundary. The second step involved 
mapping the MTL that was defined on the baseline image to the follow-up image. This 
propagation was accomplished by registering the baseline image to its corresponding 
follow-up image to produce the required transformation matrix and deformation field. 
The defined MTL in the baseline image was then propagated to the follow-up image 
using the deformation field. The difference between the volume of the MTL in the 
baseline image and follow-up image represented the atrophy that occurred between these 
time points. The technique was initially tested using a single image atlas, however we 
found that the bounding box failed to completely contain the hippocampus in some 
instances.  Since public atlases are often created using the average of multiple healthy 
brains, such atlases are also not optimal for this application.  Instead, we utilized eight 
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image sets that showed a wide range of anatomical variance and atrophy (healthy brain, 
MCI, and AD).  Using this approach we successfully labeled a relevant MTL volume in 
all subjects, which we confirmed by visual inspection. In a subset of NEC (N=10), MCI 
(N=10), and AD (N=10) subjects a method of label fusion was also tested based on a 
majority voting strategy.77,78 Eight label maps were independently produced using atlas-
based registration to define the bounding box followed by Fast Marching segmentation to 
define the VOI. Finally the VOI was refined by label fusion where majority voting was 
used to determine whether a voxel should be included in the final VOI. 
It should be noted that the smoothness of the edges of the VOI will depend on the 
objective function used to define the VOI, which incorporates a data term and a regularity 
term. The data term may include region-based and boundary-based terms. The 
regularization term is used to smooth the data term. The regularization term of the 
Diffeomorphic Demons registration79 (Appendix A) is a convolution of a Gaussian kernel 
and spatial transformation (vector field) to smooth this vector field.  In contrast, the Fast 
Marching method (a type of level-set method, Appendix B) does not use a regularization 
term. However, prior to application of the Fast Marching method, a filter is applied to the 
image (curvature anisotropic diffusion image filter),74 which smoothes the noise and 
enhances the edges.  This approach was used to increase sensitivity to minor volumetric 
changes over time. 
 
2.2.1 Study subjects 
Data used in the preparation of this article were obtained from the ADNI database 
(adni.loni.ucla.edu).  The ADNI was launched in 2003 by the National Institute on Aging 
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(NIA), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the 
Food and Drug Administration (FDA), private pharmaceutical companies and non-profit 
organizations, as a $60 million, 5-year public-private partnership.  The primary goal of 
ADNI has been to test whether serial MRI, PET, other biological markers, and clinical 
and neuropsychological assessment can be combined to measure the progression of mild 
cognitive impairment and early Alzheimer’s disease. Determination of sensitive and 
specific markers of very early AD progression is intended to aid researchers and 
clinicians to develop new treatments and monitor their effectiveness, as well as lessen the 
time and cost of clinical trials. 
The Principal Investigator of this initiative is Michael W. Weiner, MD, VA Medical 
Center and University of California – San Francisco.  ADNI is the result of efforts of 
many co-investigators from a broad range of academic institutions and private 
corporations, and subjects have been recruited from over 50 sites across the U.S. and 
Canada.  The initial goal of ADNI was to recruit 800 subjects but ADNI has been 
followed by ADNI-GO and ADNI-2.  To date these three protocols have recruited over 
1500 adults, ages 55 to 90, to participate in the research, consisting of cognitively normal 
older individuals, people with early or late MCI, and people with early AD.  The follow 
up duration of each group is specified in the protocols for ADNI-1, ADNI-2 and ADNI-
GO.  Subjects originally recruited for ADNI-1 and ADNI-GO had the option to be 
followed in ADNI-2.  For up-to-date information, see www.adni-info.org. 
 We randomly selected 1.5 Tesla T1-weighted volumetric MRI images at baseline and 
24 months in 50 NEC, 50 subjects with MCI, and 50 subjects with AD from the ADNI 
database to test the algorithm. All images were acquired using a sagittal 3D 
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magnetization-prepared rapid acquisition with gradient echo MP-RAGE sequence with 
pixel size 0.94mm×0.94mm×1.2mm; flip angle ~8°; TE ~4 ms; TR ~9 ms; TI 1000 ms; 
matrix, 256x256; 166 slices.80 Additional image preprocessing included geometric 
distortion correction, bias field correction and geometrical scaling. All subjects had the 
MMSE, Logical Memory 1 (LM) exam81 and ADAS-cog (https://ida.loni.ucla.edu/) 
cognitive assessments at baseline and 24 months interval. The MMSE scores were 
between 24-30 for NEC and MCI subjects while the MMSE scores for AD subjects were 
between 20-26. The measured change in MMSE and ADAS-cog is the difference 
between the baseline and follow-up scores. The major objective of ADNI is to provide a 
generally accessible data source for studying longitudinal changes in brain structure and 
metabolism.  
 
2.2.2 MTL segmentation 
Quantification of ∆MTL volume between baseline and 24 months was performed in 
each subject using the EXACT measurement summarized in Figure 2.1. The results were 
compared to a measure of hippocampal atrophy provided in the ADNI database produced 
by FreeSurfer (http://surfer.nmr.mgh.harvard.edu/). The technical details of the 
FreeSurfer procedure were previously published,53 and the complete process for 
hippocampus volume measurements using the longitudinal processing pipeline in ADNI 
can be found online (http://www.loni.ucla.edu/twiki/bin/view/ADNI/). The hippocampal 
volume measurements made using the longitudinal stream of FreeSurfer version 4.4 were 
provided to ADNI by the UCSF medical center. An expert (N.R.) also manually 
segmented the hippocampus in a subset of data (N=10 NEC, N=10 MCI, and N=10 AD) 
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to compare hippocampal volumes to the volume of tissue included by EXACT.  The Dice 
index82 was calculated using the baseline images for each group. 
 
2.2.3 Statistical analysis 
One-way analysis of variance (ANOVA) was performed to compare ∆MTL volume 
between the NEC, MCI and AD groups. The association between the ∆MTL from the 
EXACT measurement and change in MMSE, LM and ADAS-cog scores were evaluated 
using linear regression. The Pearson correlation coefficients were calculated between the 
volume changes in MTL from the EXACT measurement and the volume changes in 
hippocampus using the FreeSurfer software. Prism GraphPad (Prism, version 5.00; 
GraphPad Software, San Diego, CA) was used for the statistical analyses. The receiver 
operating characteristic (ROC) was also used to calculate the classification rate between 
two groups using the EXACT measurement and the FreeSurfer analysis.  The ROC curve 
analysis was performed using Prism GraphPad. 
 
2.3 Results 
Demographic characteristics are provided in Table 2.1 for all 150 subjects.  There 
was no difference between group mean ages. The MTL volume (mean ± SEM, mm3) for 
the baseline and the follow-up images in the NEC, MCI and AD groups are provided in 
Table 2.1. The segmentation of the MTL in one subject using the EXACT method is 
shown in Figure 2.2 in the coronal, axial, and sagittal planes along with a 3D rendering. 
Similarly, the segmentation of the hippocampus in the same subject using FreeSurfer is 
shown in Figure 2.3.  
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Figure 2.2 MTL segmentation using the EXACT method 
An example segmentation of the MTL using the EXACT method in one subject shown in 
Right/Left coronal (A/B), Right/Left axial (C/D) and sagittal (E) orientations. The 3D rendering 
of the MTL is shown in (F). 
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Figure 2.3 Hippocampus segmentation using the FreeSurfer method 
An example segmentation of the hippocampus using the FreeSurfer method in same 
subject shown in Right/Left coronal (A/B), Right/Left axial (C/D) and sagittal (E) 
orientations. The 3D rendering of the hippocampus is shown in (F). 
 
The manual segmentation of the hippocampus (Figure 2.4) showed that the 
hippocampus accounts for only about 40% of the total VOI included by EXACT.  
Specifically, the Dice index was 0.43 in the AD group, 0.39 for the MCI group, and 0.45 
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for the NEC group. Using an Intel Core 2 Duo processor (3.06 GHz) on an iMac10.1 
desktop computer, the total processing time to determine change in MTL volume was ~5 
hours using the EXACT method.  
 
Figure 2.4 Comparison between manual hippocampus segmentation and MTL 
segmentation using the EXACT method 
An example manual segmentation of hippocampus and amygdala and corresponding 
MTL segmentation using the EXACT method in anterior (A), middle (B) and posterior 
views (C). Amygdala (purple), hippocampus (green), and MTL (yellow) are outlined 
separately. 
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Table 2.1 Demographic information for study participants.  
M: male, SD: standard deviation, SEM: Standard Error of Mean 
 
 
Diagnosis   Software NEC MCI AD 
Number of subject (N)  50 50 50 
Age (Mean ± SD)  76.3 ± 5.0 74.5 ± 7.5 76.5 ± 6.4 
Sex (M)  27 30 23 
Baseline MMSE (Mean ± SD)  29.1 ± 1.0 27.0 ± 1.7 23.3 ± 1.8 
24 months Follow-up MMSE  
(Mean ± SD) 
 29.2 ± 0.9 25.1 ± 3.8 19.6 ± 5.4 
ΔMMSE (Mean ± SD)  -0.04 ± 1.1 1.8 ± 3.1 3.7 ± 5.0 
Baseline ADAS (Mean ± SD)  5.8 ± 3.3 11.2 ± 4.5 18.0 ± 5.7 
24 months Follow-up ADAS  
(Mean ± SD) 
 5.6 ± 3.2 13.7 ± 6.7 25.0 ± 10.9 
ΔADAS (Mean ± SD)  0.19 ± 3.3 -2.5 ± 4.9 -7.1 ± 8.4 
Baseline MTL volume  
(Mean ±SEM) mm3 
EXACT 8569.8 ± 136.1 7773.6 ± 243.1 7161.5 ± 231.1 
24 months MTL Follow-up volume 
(Mean ± SEM) mm3 
EXACT 8501.6 ±135.1 7586.4 ± 245.3 6861.1 ± 226.0 
Baseline hippocampus volume  
(Mean ±SEM) mm3 
FreeSurfer 6599.7 ± 104.0 5896.1 ± 147.4 4993.3 ± 143.0 
24 months hippocampus Follow-up 
volume (Mean ± SEM) mm3 
FreeSurfer 6441.2 ± 111.4 5481.0 ± 153.0 4589.9 ± 141.3 
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Figure 2.5 shows the average volume changes over 24 months for the MTL measured 
by the EXACT method and the change in the hippocampus measured by FreeSurfer in all 
groups. The average volume change measured using the EXACT method was 
significantly smaller than that measured using FreeSurfer in NEC (p=0.03), MCI 
(p=0.001), and AD (p=0.003). The one-way ANOVA indicated that there was a 
significant difference between three groups using the EXACT method (p<0.0001) and 
using the FreeSurfer software (p<0.0001). An unpaired t-test showed that using the 
EXACT method, there was a significant difference in MTL volume changes between the 
NEC and MCI subject groups (p=0.02), between the NEC and AD subject groups 
(p<0.0001), and between the MCI and AD subject groups (p=0.02). Similarly, an 
unpaired t-test of the FreeSurfer data also showed a significant difference in hippocampus 
between the NEC and MCI subject groups (p=0.0003), and a significant difference 
between the NEC and AD subject groups (p<0.0001). But no significant difference was 
detected between the MCI and AD subject groups.  
 
Figure 2.5 Average volume changes in three groups were measured using the 
EXACT (A) and the FreeSurfer (B) methods 
The error bars represent the standard error of the mean and asterisks show significant differences 
between groups (p<0.05). 
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Figure 2.6 shows a significant correlation (r= 0.43, p<0.0001) between the volume 
changes in the MTL using the EXACT method and volume change of the hippocampus 
using FreeSurfer including data for all groups.  
 
 
 
Figure 2.6 Association between volume changes in MTL and hippocampus volume 
changes 
Association between volume changes in MTL using the EXACT method and 
hippocampus volume change measured using the FreeSurfer method (r = 0.43, 
p<0.0001). The 95% confidence intervals for the regressions are shown as dashed lines. 
 
Figure 2.7 shows a significant association between the volume changes in the MTL 
measured by the EXACT and the MMSE score (r= 0.24, p=0.003), and between the 
hippocampus measured by FreeSurfer and the MMSE score (r= 0.39, p<0.0001). Figure 
2.8 shows a significant association between the volume changes in the MTL measured by 
EXACT and the ADAS-cog changes (r= -0.25, p=0.002), and between the hippocampus 
measured by FreeSurfer and the ADAS-cog changes (r= -0.34, p<0.0001). A significant 
correlation between the volume changes in the MTL measured by EXACT and the 24 
months LM score (r= -0.39, p<0.0001), and between the hippocampus measured by 
FreeSurfer and the 24 months LM score (r= -0.51, p<0.0001) is shown in Figure 2.9. 
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Figure 2.7 Association between volume changes and MMSE changes  
Association between the volume changes in MTL using the EXACT (A) and the MMSE 
score (r= 0.24, p=0.003). Relationship between the volume changes in hippocampus 
using FreeSurfer (B) and the MMSE changes score (r= 0.39, p<0.0001). The 95% 
confidence intervals for the regressions are shown as dashed lines. 
 
 
 
Figure 2.8 Association between the volume changes and ADAS-cog changes 
Association between the volume changes in MTL using the EXACT (A) and the ADAS-
cog changes (r= -0.25, p=0.002). Relationship between the volume changes in 
hippocampus using FreeSurfer (B) and the ADAS-cog changes (r= -0.34, p<0.0001). The 
95% confidence intervals for the regressions are shown as dashed lines. 
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Figure 2.9 Association between the volume changes and 24-month LM score 
Association between the volume changes in MTL using the EXACT (A) and the 24 
months LM score (r= -0.39, p<0.0001). Relationship between the volume changes in 
hippocampus using FreeSurfer (B) and the 24 months LM score (r= -0.51, p<0.0001). 
The 95% confidence intervals for the regressions are shown as dashed lines. 
 
A comparison of the VOI defined by the EXACT method and the VOI defined when 
incorporating label fusion by majority voting is shown in Figure 2.10.  With the label 
fusion approach the average MTL volume change was 68.0 mm3 greater across all groups 
compared to the EXACT method (N=10). With label fusion, the average ΔMTL was 54.9 
mm3 in NEC, 380.0 mm3 in MCI, and 384.0 mm3 in the AD groups (ND=10). Using the 
EXACT method in the same subject, the average ΔMTL was -49.5 mm3 in NEC, 295.2 
mm3 in MCI, and 405.4 mm3 in the AD groups. In the subset of individuals studied, the 
average volume change measured using the EXACT and label fusion methods were not 
significantly different in NEC (p> 0.05), MCI (p> 0.05), and AD (p> 0.05) groups. A 
one-way ANOVA indicated that there was a significant difference between the three 
groups using the EXACT method (p<0.001) and using the label fusion method (p<0.01). 
An unpaired t-test showed that using the EXACT method, there was a significant 
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difference in MTL volume change between the NEC and MCI groups (p=0.004), and 
between the NEC and AD groups (p=0.001). Similarly, an unpaired t-test of the label 
fusion volumes also showed a significant difference in MTL between the NEC and MCI 
groups (p=0.02), and a significant difference between the NEC and AD groups (p<0.05). 
In this subset of subjects neither method detected a difference between the MCI and AD 
groups.  
 
 
 
Figure 2.10 MTL segmentation using the EXACT method and the label fusion 
method 
An example T1-weighted coronal MRI (A) following segmentation of the MTL using the EXACT 
method (B) and the label fusion method (C) in the same subject shown. 
 
A Bland-Altman plot was used to examine the agreement between the EXACT and 
FreeSurfer methods. The Bland-Altman plot in Figure 2.11 shows the difference between 
the EXACT and FreeSurfer volume change measurements as a function of their average. 
The mean bias (108.4) and the 95% limit of agreement (265.8) computed as the mean 
bias ± SD of the difference between the two techniques are also shown. The results 
indicate that the FreeSurfer technique calculated larger changes in volume than the 
EXACT method. The ROC curve analysis between two groups using the EXACT method 
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and the FreeSurfer software showed that the ability to classify subjects between NEC and 
AD groups with EXACT was slightly lower (76%) compared to FreeSurfer (80%). But, 
the ability to classify subjects between MCI and AD groups with EXACT was slightly 
higher (60%) compared to FreeSurfer (57%). The Z distribution indicates that there was 
no significant difference between the areas under the two ROC curves of NEC vs AD and 
MCI vs AD (p>0.05). 
 
Figure 2.11 Bland-Altman plot between the FreeSurfer and the EXACT method  
The mean difference (±SD) between FreeSurfer and EXACT was 108.4 ± 265.8. The bold dashed 
line indicates the mean difference and the dashed lines indicate the 95% limits of agreement. 
 
2.4 Discussion 
A novel fully automated method for segmentation of the MTL (EXACT) was 
developed that combined multiple atlas-based registration with a Fast Marching 
algorithm. The EXACT method was used to measure the change in MTL volume for 50 
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NEC, 50 subjects with MCI and 50 subjects with AD over a 24 months interval. The 
volume changes in the MTL correlated with changes in cognitive function measured 
using the MMSE and the ADAS-cog scores, as well as memory performance using the 
LM score.  The volume of interest measured by EXACT does not correspond exclusively 
to the hippocampus.  Rather it is a medial temporal lobe volume to which the 
hippocampus contributes ~ 40%. Comparison between manual tracings and the EXACT 
VOI indicated that EXACT also includes primarily the amygdala, fibers associated with 
the amygdala, and the parahippocampal gyrus. 
The absolute change in MTL volume measured using the EXACT approach was 
slightly lower than the change measured by FreeSurfer in the hippocampus. However, 
this result was expected as FreeSurfer has been shown to significantly overestimate the 
rate of measured mean atrophy in NEC, MCI and AD groups compared to multi-template 
hippocampal segmentation.36,83 When comparing the rate of atrophy measured over two 
years with EXACT to other methods, the values appear lower due in part to a larger MTL 
baseline measurement; the VOI defined by EXACT also includes tissue outside the 
hippocampus. Specifically, the mean MTL rate of atrophy measured over two years by 
EXACT was 0.7% in NEC, 2.7% in MCI and 4.2% in AD subjects while FreeSurfer 
measured hippocampal atrophy of 2.5% in NEC, 5.9% in MCI, and 8.0% in AD. 
Similarly, the 24 month mean rate of atrophy measured by EXACT was smaller than that 
recently reported by Nestor et. al.36 in the hippocampus using multi-atlas based 
segmentation: 2.5% for NEC (n= 173), 5.0% for MCI (n= 253) and 7.9% for AD (n= 
111). These differences may also be explained by differing sample sizes. More 
importantly, using the EXACT method, differences were detected between all three 
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groups (NEC, MCI, AD) while the FreeSurfer measurement only detected differences 
between NEC and MCI, as well as NEC and AD. The observed significant difference in 
∆MTL volume between MCI and AD subjects suggests that ∆MTL volume may provide 
useful to differentiate between MCI and AD subjects.  However both EXACT and 
FreeSurfer showed similar classification accuracy for NEC versus AD (76-80%) and for 
MCI versus AD (57-60%).  Previous studies have also shown similar results.  For 
example, Shen et. al.84 performed a fully automated atlas-based segmentation using a 
template-based approach to obtain normalized hippocampal and amygdala volumes 
between subjects with AD, subjects with amnestic MCI (aMCI) and healthy control 
subjects. By using the area under the ROC curve on normalized hippocampus volume, 
they achieved a classification rate of 86-90% for the left hippocampus and of 85-87% for 
the right hippocampus for AD versus controls. However, they did not compare the 
classification rate between their subjects with aMCI and AD as well as examine the 
automated segmentation results with manual tracing. The EXACT method showed that 
the area under the ROC curve on volume changes was 78% in the left MTL and 75% in 
the right MTL between NEC and AD groups. However, a statistical comparison of the 
area under the ROC curves is not possible.  
Both the EXACT and FreeSurfer techniques produced a significant relationship 
between change in volume and the change in MMSE and the ADAS-cog cognitive scores 
as well as 24 months LM score. With the EXACT method a positive correlation was 
observed between the volume changes in MTL and the change in MMSE score, and an 
inverse correlation was observed between the change in MTL and the change in ADAS-
cog and LM scores, suggesting that MTL atrophy is related to cognitive function and 
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memory performance. Previous studies using manual or semi-automated measures of 
MTL volumes have also shown a significant correlation between the rate of clinical 
decline and MTL atrophy in elderly patients over 12 months.85,86 Arlt et. al. showed 
correlations between hippocampus volume and neuropsychological tests for aMCI and 
AD groups.87 However, they did not investigate the classification rate of this fully 
automated technique or comparison with manual segmentation. Wolz et. al.88 proposed an 
automated method to measure hippocampal atrophy by segmenting longitudinal MR 
images from the ADNI database. They used an energy function based on Markov random 
fields (MRF) in combination with the graph cuts method41 and showed a significant 
correlation (r= 0.30, p<0.001) between MMSE changes and hippocampal volume 
changes after 1 year. Similarly in the current study, we found a significant association 
between MTL volume changes after 2 years and the change in MMSE score (r= 0.24, 
p=0.003). Although both studies demonstrated a similar association, there are several 
important differences between the approaches. First, we segmented the VOI in the 
baseline image and propagate this VOI to follow-up image. In contrast, Wolz et. al.88 
proposed a method that segments hippocampus simultaneously in all longitudinal images. 
Second, their initial probabilistic atlas was created from healthy subjects, while EXACT 
selects the best atlas from a series of eight possibilities. Finally, they used the graph cuts 
method41 to segment longitudinal MR images, while we applied the Fast Marching 
method to the baseline images. 
Several studies have performed manual or semi-automated segmentation of brain 
structures, which is time-consuming and is characterized by low intra- and inter-observer 
reproducibility depending on the level of experience of the observers.89-91 Although 
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several automated hippocampus segmentation methods have been proposed,92,93 these 
studies used single atlas-based segmentation potentially decreasing accuracy. In contrast, 
the current study used eight separate atlases to increase segmentation accuracy. Since 
EXACT requires significantly less processing time, it would be advantages in situations 
where large datasets must be analyzed. 
Potential limitations of the algorithm are that the segmentation of the MTL in the 
baseline and follow up images are not independent (baseline images are registered to 
follow-up images).  However this approach was taken to increase the precision of the 
atrophy measurement in this small structure.  It should also be noted that the contour of 
the volume of interest is treated differently in the baseline and follow-up images.  We 
expect that volumetric changes that occur between time points in one individual will be 
subtle.  Therefore, we chose to use a regularization term in the diffeomorphic registration 
that was less severe than the smoothing filter used with the Fast Marching method so that 
the method would be sensitive to minor volumetric changes. Since the EXACT 
measurement is designed to be sensitive to atrophy, accurately defining the hippocampus 
is less important than sensitivity to change within the prescribed volume. Also, only a 
small number (eight) of atlases were used for selection, which should be increased for 
larger datasets.  However the use of a small number of atlases is likely not a major 
limitation because the accuracy of the definition of the MTL is less important than 
sensitivity to change over time. Including more atlases may further increase the 
robustness of the technique in cases of extreme anatomical variability, however would 
also increase computation time.  Optimizing the number of atlases will be the focus of 
future work. The number of atlases used can impact the quality of the final segmentation.  
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The purpose of the atlas registration is to define a bounding box around the medial 
temporal lobe region of interest. As such, the demands on this registration step are light. 
However in cases of severe atrophy, the bounding box may fail to include the 
hippocampus if there are significant differences between the image and the atlas.  This 
limitation was overcome in the current study by using multiple atlases with varying 
anatomy.  Using eight atlases that spanned a wide range of atrophy conditions we 
successfully defined a MTL region label map in all subjects.  Using an atlas fusion 
technique did not change the results and increased computation time. Finally, the method 
described in the current study is biased, since the baseline and follow-up volumes are 
measured using different regularization functions. Recently, several unbiased 
methods88,94,95 have also been proposed for longitudinal studies. 
 
2.5 Conclusions 
In the present study, a fully automated longitudinal MTL atrophy measurement 
called EXACT was developed. The EXACT measurement showed significant differences 
in MTL atrophy over two years in normal elderly controls, subjects with mild cognitive 
impairment, and subjects with Alzheimer’s disease.  The MTL atrophy also correlated 
with decline in cognitive performance. This method is applicable to large datasets and 
could be incorporated in clinical evaluation in the future. 
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2.6 Appendices 
Appendix A. 
In Demons registration, an energy function is optimized to align two images by 
introducing correspondences between image pixels and applying a regularization term as 
prior knowledge to smooth the transformation of spatial points. The energy function can 
be formulated as shown in Eq. (2.1) and described in.79 
 
Where  represents the spatial uncertainly on the correspondences between image 
pixels, ,  , the regularization term  
and   is a similarity metric using the transformation of spatial points given by Eq. 
(2.2) in.79 
 
where  is the region of overlap between F and .   is a transformation of 
spatial points (s) belonging to the moving image M. To optimize Eq. (2.1) a spatial 
transformation is chosen. Given s, the vector field (u) is updated by minimizing Eq. (2.3) 
with respect to u using a Gauss-Newton iterative method.79 Then the regularization is 
measured by convolution of a Gaussian kernel and vector field. This procedure performs 
iteratively till convergence.  
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This Demons algorithm is made Diffeomorphic by computing an exponential of the 
vector field u with the spatial points s, prior to regularization. 
 
Appendix B. 
Details of the Fast Marching segmentation method can be found in.62,74,96 Briefly, in 
the Fast Marching segmentation method, the goal is to solve the Eikonal equation 
. In its discrete form, it is given by Eq. (2.4) presented in.96-98 
 
where , and 
similarly for the y and z directions.  In practice, the method propagates a contour curve in 
2D or a contour surface in 3D with the speed function F1. Where is the time 
when the speed function reaches voxel .  
The Fast Marching method has two phases: an initialization and propagation step. 
Each voxel has a value for T that is updated as the contour propagates. Voxels meeting a 
defined time threshold are included within the contour. The speed term in the differential 
equation is determined from the gradient magnitude. The curve propagates slowly near 
large image gradients but moves quickly when image gradients are small. Using this 
strategy, the contour propagates quickly until it nears the edge of an anatomical structure 
at which point it slows down. The contour propagates continuously over time and stops 
once a defined time threshold has been reached.74 
∇T F1 =1
1
F1 {i, j,k}
2 =max(D{i, j,k}
−x T, 0)2 +min(D{i, j,k}
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−y T, 0)2 +
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CHAPTER 3: Spontaneous blood oxygen level dependent MRI 
signal variations are decreased in Alzheimer disease 
 
The work presented in this chapter is in preparation for submission for publication. 
 
Samaneh Kazemifar, Kathryn Manning, Nagalingam Rajakumar, Francisco A. Gómez, 
Andrea Soddu, Michael J. Borrie, Ravi S. Menon and Robert Bartha PhD 
 
3.1 Introduction 
Alzheimer disease is considered to be a progressive neurodegenerative condition 
clinically characterized by cognitive dysfunction and memory impairments1 that appear 
to result from the pathological accumulation of amyloid plaques and neurofibrillary 
tangles.2,3 Brain atrophy measured by magnetic resonance imaging (MRI) has been 
established as an important biomarker associated with disease progression and treatment 
response.4-6 Another established biomarker is reduced regional uptake of 18F labeled 
fluorodeoxyglucose (FDG) measured using positron emission tomography (PET),7 
indicating lower glucose metabolism in Alzheimer’s disease.8,9 
Neuronal activity can also be inferred from blood oxygen level dependent (BOLD) 
contrast as exploited in functional MRI (fMRI).  More recently, resting-state (RS)-fMRI 
measures of spontaneous low frequency fluctuations (< 0.1 HZ) in the BOLD signal have 
been used to identify functionally connected brain regions (networks) without the 
performance of an overt task.10,11 Smith and colleagues12,13 have shown that several 
resting state networks can be identified, and may be altered in Alzheimer’s disease.  For 
example, multiple studies have found resting RS-fMRI can be used to show disrupted 
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connectivity between the hippocampus and other brain regions in Alzheimer 
disease.12,14,15 Furthermore, the interconnectivity of brain regions can be used to classify 
subjects with Alzheimer disease, amnestic mild cognitive impairment, and healthy 
elderly.16 
A number of different statistical and mathematic approaches have been used to infer 
functional connectivity from RS-fMRI data.  One common approach is to use the a-priori 
selection of a seed region of interest (ROI)17-19 to determine the correlation between the 
mean BOLD signal time course within the ROI and the BOLD signal time courses of all 
other pixels in the brain. However the requirement for a-priori seed selection makes it 
difficult to examine the functional connectivity across the whole brain. Another popular 
multivariate technique for analyzing whole brain connectivity is independent component 
analysis (ICA).20-22 This approach does not require a-priori information and decomposes 
the BOLD signal into a set of spatial and temporal components that are maximally 
statistically independent.23 The ICA method is also an efficient approach to extract 
scanner noise, as well as physiological and motion artifacts from the BOLD signal.24 One 
of the major challenges with the ICA technique is to determine which components 
represent physiologically relevant networks, and which components represent noise. 
However methods now exist to differentiate neuronal from non-neuronal components.25 
Brain regions associated with the default mode network (DMN) have been repeatedly 
implicated in the pathogenesis of Alzheimer’s disease.12,26 FDG-PET studies have shown 
reduced glucose metabolism in the medial temporal cortex, hippocampus, and posterior 
cingulate cortex.27-29 Decreased functional connectivity in the DMN has also been 
associated with increased amyloid deposition measured using Pittsburgh compound B 
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PET.30,31 In addition, several studies in healthy controls have shown a relationship 
between glucose metabolism measured by PET and the RS-fMRI signal.  For example, 
Di et. al. showed that metabolic activity was correlated with IC maps of the BOLD signal 
in regions that are functionally connected.32 Similarly, Tomasi et. al.33 measured the 
amplitude of the RS-fMRI signal and glucose metabolism by FDG-PET and 
demonstrated that higher metabolism was correlated with a higher amplitude of the RS-
fMRI signal in the cerebellum, occipital, and parietal cortices.  Finally, Riedl et. al.34 
found a correlation between local brain activity in specific regions of interest measured 
from FDG-PET data and functional connectivity measured by RS-fMRI using seed-based 
methods. 
Previous RS-fMRI studies have shown a reduction in functional connectivity 
between structures based on the strength of the correlation in the BOLD signal.18,35 Here, 
we define a novel metric of brain activity based on first-order texture feature defined as 
the standard deviation of the magnitude of the BOLD fluctuation. The purpose of this 
study was to determine whether this new metric could be used to accurately differentiate 
healthy individuals from people with mild Alzheimer disease.  The hypothesis is that the 
fluctuation of the magnitude of the BOLD signal as a function of time is related to 
neuronal activity and therefore will also correlate with FDG-PET measures of glucose 
metabolism.  The goal is to demonstrate the efficacy of a new biomarker of Alzheimer’s 
disease based on the fluctuation of the magnitude of the RS-fMRI signal. Furthermore, 
we examined the association between the fluctuation magnitude of the neuronal derived 
RS-fMRI signal and FDG-PET. 
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3.2 Theory 
In this study, we propose a brain activity measurement derived directly from the RS-
fMRI signal.  The RS-fMRI signal can be represented as an i x v matrix, where i 
represents each pixel, and v represents the number of volumes acquired in the fMRI 
acquisition. The ICA method decomposes the RS-fMRI signal into: 1) an i x n matrix of 
independent components (IC) spatial maps, where n represents the number of 
components, and 2) an n x v matrix of mixing weights (W) or IC time-courses. Here, the 
number (k) of legitimate ICs were identified using a support vector machine (SVM) 
classifier25 that included only the neuronal components (NC) with goodness-of-fit (GoF) 
≥ 0.01 (Figure 3.1A).  The weighting function for each neuronal component, Wk(tv) is 
then multiplied (Hadamard product, Eq. 3.1, Figure 3.1B) with the equal length vector 
given by the RS-fMRI time series for each pixel, Si(tv), generating a new vector of equal 
length BSAi,k(𝑡!):   
𝐵𝑆𝐴!,!(𝑡!) =   𝑆!(𝑡!)   ∘𝑊!(𝑡!)                                                                                                                                                                                                  [3.1] 
where BSAi,k represents the BOLD signal amplitude (BSA) for each neuronal 
component k in pixel i.  Then, the standard deviation (SD) is calculated for BSAi,k and is 
multiplied with the neuronal component (NCi,k) (Figure 3.1C). The sum of this metric 
(Eq. 3.2, Figure 3.1D) for all neuronal components in a pixel represents the neuronal 
activity and is used to produce a neuronal activity map.    
𝑁𝑒𝑢𝑟𝑜𝑛𝑎𝑙  𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦! =    𝑆𝐷(𝐵𝑆𝐴!,!(𝑡!))  ×  𝑁𝐶!,!
!
!!!
                                                                                                          [3.2] 
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Figure 3.1 Schematic diagram of the brain activity metric calculated from the RS-
fMRI signal in one pixel 
The signal shown is a graphical representation of the vector data. (A) Neuronal time course 
(NTC) are defined by the ICA and verified using a support vector machine classifier. (B) The 
Hadamard product of each neuronal time course is taken with the RS-fMRI signal. (C) The 
standard deviation of the resulting signal is multiplied by the neuronal component. (D) The 
square root of the contribution of each NTC is added to create a measure of neuronal activity. 
 
3.3 Methods 
3.3.1 Study subjects 
Data used in the preparation of this article were obtained from the Alzheimer’s 
Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu).  The   ADNI   was   
launched   in   2003 as a public-private partnership, led by Principal Investigator Michael 
W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic 
resonance imaging, positron emission tomography, other biological markers, and clinical 
and neuropsychological assessment can be combined to measure the progression of mild 
cognitive impairment and early Alzheimer’s disease. 
To test the algorithm, this study included data from 15 normal elderly controls (NEC) 
and 15 subjects with probable Alzheimer disease of mild severity obtained from the 
ADNI database.  We included participants that had 3.0 Tesla T1-weighted anatomical 
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scans and10-minute RS-fMRI data acquisitions.  A subset of this group (13 NEC, and 11 
subjects with mild Alzheimer disease) also had an FDG-PET scan available. Structural 
T1-weighted images were obtained using a sagittal 3D magnetization-prepared rapid 
acquisition with a gradient echo MP-RAGE sequence with pixel size 
1mm×1mm×1.2mm; flip angle ~9°; TE ~4 ms; TR ~7 ms; matrix, 256x256; 170 
slices.36RS-fMRI scans were acquired using a single shot echo planer imaging (EPI) 
pulse sequence with pixel size 3.3mm×3.3mm×3.3mm; flip angle 80.0°; TE 30 ms; TR 
~3000 ms; matrix = 64x64; 48 slices.37 FDG-PET images were acquired using similar 
protocols on all PET scanners but varied somewhat in resolution, spacing, and dimension.  
However images were normalized and motion corrected38 prior to analysis. The FDG-
PET scans consisted of six-5 minute frames acquired starting 30 minutes after FDG 
injection.38 All frames were registered to the first frame and then averaged to produce a 
single static image. All subjects were also evaluated with the mini mental state 
examination (MMSE)39 to assess cognition. In addition, CSF biomarkers including total 
Tau protein (Tau), phosphorylated Tau protein (P-Tau) and amyloid-β (Aβ1-42) were 
obtained for all subjects (https://ida.loni.usc.edu/). 
 
3.3.2 RS-fMRI analysis 
The brain was extracted from the RS-fMRI data and the anatomical T1-weighted 
images using the brain extraction tool (BET) in the FSL software (functional MRI of the 
brain (FMRIB) Software Library, Department of Clinical Neurosciences, University of 
Oxford, UK, http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FSL). The brain extracted fMRI data 
were preprocessed, aligned and co-registered to the MNI-152 space using the fMRI 
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expert analysis tool (FEAT) in FSL. An initial smoothing (full-width half-maximum of 6 
mm) was applied before ICA decomposition.  The ICA method (30 components) was 
performed using the group ICA of the fMRI toolbox (GIFT).40 ICA was followed by a 
multiple-template matching technique and neuronality test to identify neuronal 
components. The multiple-template matching technique and neuronality test was 
implemented by Demertzi and colleagues.25 Then, a brain activity map was constructed 
from the neuronal components as described in the Theory section and co-registered to the 
MNI-152 standard image using linear and non-linear registration methods. Co-
registration of the brain activity map to the anatomical image was conducted using 
Statistical Parametric Mapping (SPM8, Wellcome Department of Neurology, London, 
UK; www. fil.ion.ucl.ac.uk/spm). ROIs were defined in the MNI-152 image using the 
structural segmentation method called FMRIB’s integrated registration and segmentation 
tool (FIRST) in FSL because it is easily accessible to the research community and 
automated. Finally, the mean intensity from each ROI in the brain activity map was 
measured.  A schematic representation of the steps involved in making the brain activity 
measurement is provided in Figure 3.2. 
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Figure 3.2 Brain activity from RS-fMRI. Schematic diagram of the brain activity 
(BOLD signal amplitude) measurement in different brain regions  
(A) Steps involved in calculating the brain activity maps from the RS-fMRI. (B) Regions of 
interest extracted from MNI-152 space. (C) Activity maps within each region of interest from one 
subject. 
 
3.3.3 Volumetric analysis 
The FSL software was used to measure the volumes of the accumbens, amygdala, 
hippocampus, caudate nucleus, thalamus, pallidum, putamen, and whole brain from the 
T1-weighted image of each subject using a method similar to that previously described.41 
The volumes were normalized to the whole brain volume in each subject. 
 
 
 
99 
3.3.4 FDG-PET analysis 
The brain was also extracted from the FDG-PET images using the BET tool in FSL. 
A partial volume correction method was applied to each data set using partial volume 
correction structural functional synergistic resolution recovery (PVC_SFSRR) software.42 
This software performs pre-processing steps including co-registration of the FDG-PET 
with the structural image, segmentation and smoothing (8 mm), and finally partial 
volume correction. The corrected FDG-PET image was co-registered to the MNI-152 
template. The predefined ROIs in the MNI-152 image were applied to the co-registered 
FDG-PET image. The standardized uptake value (SUV) of each ROI was then 
normalized to the mean SUV of the cerebellum to obtain the SUV ratio (SUVR) as this 
has been previously shown43 to be unchanged in healthy subjects at the early stages of 
Alzheimer disease.   
3.3.5 Statistical analysis 
Prism GraphPad (Prism, version 6.00; GraphPad Software, San Diego, CA) and 
Matlab toolbox (version R2010a) were used for the statistical analyses. One-way 
ANOVA was used to compare brain activity between the NEC and Alzheimer disease 
groups (p <0.05 considered significant).  If a significant group effect was observed, the p-
values associated with follow-up group comparisons between brain regions were 
Bonferroni corrected for multiple comparisons. The association between the brain 
activity measured from the RS-fMRI, MMSE score, and CSF biomarkers were evaluated 
using linear regression. The Pearson correlation coefficients were calculated between the 
brain activity in gray matter using RS-fMRI and FDG-PET and considered significant 
with p <0.05.  
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3.3.6 Classification model 
To determine if the RS-fMRI derived brain activity measurement was a suitable 
biomarker to differentiate patients with mild Alzheimer disease and healthy elderly 
controls, a SVM classifier was used.  Specifically, a linear SVM44 was trained and tested 
on the feature space.  Regions of interest were selected based on the observed differences 
between groups for either the brain activity metric or FDG-PET measured glucose 
metabolism.  A leave-one-out-test was used as a cross-validation to predict the label for 
each test subject (not involved in the training phase). The accuracy, sensitivity, and 
specificity were determined after each subject was assessed as the test subject.  In the first 
analysis, RS-fMRI brain activity in the hippocampus and accumbens, FDG-PET in the 
hippocampus, and hippocampal volume were evaluated separately. In a second analysis, 
FDG-PET and RS-fMRI modalities were evaluated independently incorporating data 
from both the hippocampus and amygdala. In a third analysis, we combined the 
volumetric and RS-fMRI information from the hippocampus and accumbens. 
 
3.4 Results 
3.4.1 Brain maps of Neuronal activity and glucose metabolism 
Demographic characteristics are provided in Table 3.1 for all 30 subjects.  There was 
no difference between group mean ages, however as expected, there was a significant 
difference in the MMSE score (p<0.0001, two-tailed t-test) between the two groups. 
Montreal neurological institute-152 (MNI-152) template T1-weighted images (Figures 
3.3A, 3.3B) in coronal, sagittal, and axial planes are shown with corresponding 
standardized uptake value ratio (SUVR) glucose metabolism maps from the FDG-PET 
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scan in one healthy subject (Figure 3.3C) and the healthy group average (Figure 3.3G); as 
well as one subject with Alzheimer disease (Figure 3.3D) and the Alzheimer disease 
group average (Figure 3.3H). Corresponding brain activity maps measured from the RS-
fMRI in the same subjects (Figures 3.3E, 3.3F) and group averages (Figures 3.3I, 3.3J) 
are also provided.  There is a visible decrease in signal in the subject with Alzheimer 
disease throughout the brain measured by both modalities.  
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Table 3.1 Demographic information for study participants. 
 
 RS-fMRI 
NEC 
RS-fMRI 
Alzheimer disease 
FDG-PET  
NEC 
FDG-PET 
Alzheimer disease 
 Number of subject (N) 15 15 13 11 
Age (years) (Mean±SD) 73.5 ± 6.2 73.3 ±8.0 74.4 ± 6.1 70.9 ± 7.2 
MMSE (Mean±SD) 28.9 ± 1.2 21.6 ± 2.1* 29.0 ± 1.1 21.8± 2.3* 
Sex (F) 10 10 9 7 
Tau (pg/ml) (Mean±SEM) 66.3± 9.8 164.5±22.8** 63.8±9.6 182.5±28.2** 
P-Tau (pg/ml) (Mean±SEM) 38.9 ± 10.0 62.0±7.7 40.7±11.1 68.1±9.5 
Aβ1-42 (pg/ml) (Mean±SEM) 192.5± 16.1 132.3±5.4** 179.0±15.0 131.2±7.3** 
 
*p<0.05 (two-tailed) and **adjusted p value (Bonferroni) between NEC and Alzheimer 
disease within a single imaging modality 
F= female; SEM= standard error of mean, SD= standard deviation, NEC= normal elderly 
controls, FDG-PET= 18fludeoxyglucose-PET, RS-fMRI= resting state functional MRI, 
MMSE= mini mental state examination, P-Tau= phospho-Tau, Aβ1-42= amyloid beta1-42 
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Figure 3.3 Brain activity and glucose metabolism maps 
MNI-152 T1-weighted anatomical images in coronal, sagittal, and axial orientations (A, B).  
Corresponding FDG-PET SUVR images of glucose metabolism from a healthy subject (C), and 
healthy group average (G); a patient with Alzheimer disease (D), and the Alzheimer disease 
group average (H).  Brain activity maps obtained using RS-fMRI in the same healthy subject (E), 
and the healthy group average (I) and the patient with Alzheimer disease (F), and the Alzheimer 
disease group average (J).  
 
3.4.2 Comparison of regional brain activity and glucose metabolism 
The average brain activity measured from RS-fMRI (Figure 3.4) is shown for the 
cerebellum, amygdala, thalamus, accumbens, caudate, pallidum, hippocampus, and 
putamen regions for the NEC and Alzheimer disease groups. Similarly, the average 
relative rate of glucose metabolism (Figure 3.5) is provided for the same regions 
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measured by FDG-PET for the NEC and Alzheimer disease groups. A one-way ANOVA 
indicated that there was a significant difference between the two groups in RS-fMRI 
brain activity (p<0.0001) and FDG-PET measured glucose metabolism (p<0.0001). In 
follow-up comparisons, the difference in brain activity measured by RS-fMRI in both 
sides of the accumbens (adjusted p=0.04) and differences in relative glucose metabolism 
measured using FDG-PET in the amygdala (adjusted p=0.02), and hippocampus 
(adjusted p=0.006) remained significant following Bonferroni correction. A one-way 
ANOVA indicated that there was also a significant difference between these groups in 
the Tau, P-Tau and Aβ1-42 cerebral spinal fluid (CSF) levels (p<0.0001). Follow-up 
comparisons showed that there were significant differences in both Tau (adjusted 
p<0.0001), and Aβ1-42 (adjusted p=0.006) following Bonferroni correction for multiple 
comparisons. As expected, a one-way ANOVA also showed a significant difference in 
normalized brain volumes between the NEC and Alzheimer disease groups (p<0.0001). 
Follow-up comparisons showed significant differences in normalized volume measured 
using MRI in the hippocampus (p=0.01) between the two groups. 
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Figure 3.4 Regional brain activity 
The average brain activity measured by RS-fMRI in NEC and Alzheimer disease subjects in the 
cerebellum, amygdala, thalamus, accumbens, caudate, pallidum, hippocampus, and putamen. The 
error bars represent the standard error of the mean and asterisks show significant differences 
between groups (Bonferroni adjusted p value). 
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Figure 3.5 Regional glucose metabolism 
The average glucose metabolism measured by FDG-PET SUVR in NEC and Alzheimer disease 
subjects in the amygdala, thalamus, accumbens, caudate, pallidum, hippocampus, and putamen. 
The error bars represent the standard error of the mean and asterisks show significant differences 
between groups (Bonferroni adjusted p value). 
 
3.4.3 Comparison of neuronal components in NEC and Alzheimer disease groups 
The average ± SD of the number of neuronal components was 6.4 ± 1.5 for the NEC 
group and 5.0 ±1.2 for the Alzheimer disease group. Unpaired t-test (two-tailed) showed 
significantly fewer neuronal components in the Alzheimer disease group compared to the 
NEC group (p=0.007). Pooling all subjects, the average number of neuronal components 
was positively correlated with MMSE score (r= 0.30, p=0.002).  The average ± SD of the 
RS-fMRI neuronal activity (Eq. 3.2) summed across all neuronal components in whole 
brain was 54.8 ± 18.3 in the NEC group and 40.6 ± 10.4 in the Alzheimer disease group.  
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Unpaired t-test (two-tailed) showed significantly lower neuronal activity in the Alzheimer 
disease group compared to the NEC group (p=0.01) (Figure 3.6).  
 
 
Figure 3.6 Component specific brain activity maps in one healthy subject and one 
subject with Alzheimer disease 
Each image represents the square root of the standard deviation of the magnitude of the BOLD 
signal fluctuation.  In this example, data from each identified neuronal component is provided in 
a different row.  Eight neuronal components were identified in the healthy subject while only six 
neuronal components were identified in the subject with AD. 
3.4.4 Association between neuronal activity and cognitive function 
The relationship between RS-fMRI brain activity and clinical cognitive 
measurements are shown in Figure 3.7 when pooling all groups. There was a significant 
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correlation between the MMSE score and brain activity in the cerebellum (r= 0.50, 
p=0.007), amygdala (r= 0.47, p=0.009), thalamus (r= 0.42, p=0.02), accumbens (r=0.48, 
p=0.008), caudate (r= 0.41, p=0.02), pallidum (r= 0.44, p=0.01), hippocampus (r= 0.44, 
p=0.01), and putamen (r= 0.41, p=0.02). 
 
 
Figure 3.7 Relationship between mean brain activities measured using RS-fMRI and 
cognition function  
The 95% confidence intervals for the regressions are shown as dotted lines. Association between 
MMSE score and brain activity in cerebellum (r= 0.50, p=0.007, A), amygdala (r= 0.47, p=0.009, 
B), thalamus (r= 0.42, p=0.02, C), accumbens (r= 0.48, p=0.008, D), caudate (r= 0.41, p=0.02, E), 
pallidum (r= 0.44, p=0.01, F), hippocampus (r= 0.44, p=0.01, G), and putamen (r= 0.41, p=0.02, 
H). 
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3.4.5 Association between neuronal activity and Aβ1-42 
The relationship between RS-fMRI brain activity and Aβ1-42 CSF level is shown in 
Figure 3.8 for all subjects. There was a significant correlation between the RS-fMRI 
brain activity and Aβ1-42 in the cerebellum (r= 0.40, p=0.03), amygdala (r= 0.51, 
p=0.004), accumbens (r= 0.37, p=0.04), pallidum (r= 0.41, p=0.02), and putamen (r= 
0.41, p=0.02). 
 
 
Figure 3.8 Relationship between mean brain activity measured using RS-fMRI and 
CSF derived Amyloid Beta1-42.  
The 95% confidence intervals for the regressions are shown as dotted lines. Association between 
the brain activity and Aβ1-42 in the cerebellum (r= 0.40, p=0.03, A), amygdala (r= 0.51, p=0.004, 
B), accumbens (r= 0.37, p=0.04, C), pallidum (r= 0.41, p=0.02, D), and putamen (r= 0.41, 
p=0.02, E). 
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3.4.6 Association between neuronal activity and glucose metabolism 
A voxel by voxel correlation between gray matter RS-fMRI brain activity and the 
rate of glucose metabolism from the FDG-PET is shown in Figure 3.9 for one NEC (r= 
0.81, p<0.0001) and subject with Alzheimer disease (r= 0.77, p<0.0001).  Correlations 
were similar in all subjects (Figures 3.10 and 3.11). The average r- value ± SD associated 
with the correlation between gray matter activity measured using RS-fMRI and the rate 
of glucose metabolism measured using FDG-PET was 0.77 ± 0.04 for the NEC group and 
0.73 ± 0.03 for the Alzheimer disease group.  The average y-intercept ± SD for the NEC 
group was 0.23 ± 0.03 and for the Alzheimer disease group was 0.23 ± 0.03. 
 
 
Figure 3.9 Relationship between glucose metabolism using FDG-PET and brain 
activity measured by RS-fMRI   
Voxel by Voxel correlation of pixel intensity in gray matter (r= 0.81, p<0.001) from a healthy 
subject (A) and a patient with Alzheimer disease (B) (r= 0.77, p<0.001) between brain activity 
using RS-fMRI and corrected glucose metabolism using FDG-PET SUVR. 
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Figure 3.10 Correlation of pixel intensity between RS-fMRI and FDG-PET SUVR in 
healthy group 
Voxel by voxel correlation of pixel intensity in the gray matter of healthy subjects between brain 
activity using RS-fMRI and corrected glucose metabolism using FDG-PET SUVR. 
 
 
Figure 3.11 Correlation of pixel intensity between RS-fMRI and FDG-PET SUVR in 
Alzheimer disease group 
Voxel by voxel correlation of pixel intensity in the gray matter of Alzheimer disease subjects 
between brain activity using RS-fMRI and corrected glucose metabolism using FDG-PET SUVR. 
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3.4.7 Comparison of classification accuracy 
The classification accuracy of subjects using brain activity measured by RS-fMRI 
and relative glucose metabolism rate measured using FDG-PET is provided in Table 3.2. 
The greatest classification accuracy, sensitivity, and specificity were obtained when using 
FDG-PET measurement from the hippocampus. The classification model that used 
glucose metabolism in the hippocampus measured by FDG-PET achieved 85% average 
accuracy, 84% sensitivity and 85% specificity (Table 3.2). The models that used brain 
activity in the hippocampus or accumbens resulted in a lower accuracy, sensitivity, and 
specificity (Table 3.2). However, the model that combined normalized hippocampal 
volume and neuronal activity of RS-fMRI from the hippocampus achieved 80% average 
accuracy, 72% sensitivity and 89% specificity, providing a similar accuracy and 
specificity to that observed with FDG-PET glucose metabolism in the hippocampus. 
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Table 3.2 Classification results for RS-fMRI brain activity, glucose metabolism and 
volumetric measurements  
Glucose metabolism measured by FDG-PET SUVR, and normalized volume measured using 
MRI. 
 
  
SVM_linear (leave-one-out-test) 
 
Accuracy 
 
Sensitivity 
 
Specificity 
RS-fMRI (Hippocampus) 0.75 0.70 0.78 
RS-fMRI (Accumbens) 0.56 0.42 0.68 
RS-fMRI (Hippocampus, and Amygdala) 0.65 0.57 0.71 
FDG-PET (Hippocampus) 0.85 0.84 0.85 
FDG-PET (Hippocampus, and Amygdala) 0.76 0.84 0.68 
MRI (Hippocampus) 0.67 0.64 0.70 
RS-fMRI (Accumbens) + MRI (Hippocampus) 0.70 0.63 0.73 
RS-fMRI (Hippocampus) + MRI (Hippocampus) 0.80 0.72 0.89 
 
SVM= support vector machine, FDG-PET= 18fludeoxyglucose-PET, RS-fMRI= resting 
state functional MRI, ROI= region of interest. 
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3.5 Discussion 
In this study we define a new metric related to neuronal activity based on the square 
root of the temporal standard deviation of the RS-fMRI signal summed across all 
neuronal components within a pixel. As a proof of principle, this new RS-fMRI based 
biomarker was used to compare brain activity in normal elderly subjects and patients with 
mild Alzheimer disease. The brain activity measurement is dependent on both the number 
of neuronal components and the temporal fluctuation associated with each component. 
Overall lower brain activity was observed in the mild Alzheimer disease group, 
particularly within the accumbens. A similar comparison in the same subjects using 
FDG-PET also showed overall group differences indicating lower glucose metabolism in 
the amygdala, and hippocampus. In a pixel-by-pixel analysis, brain activity derived from 
RS-fMRI was found to be strongly correlated with glucose metabolism measured by 
FDG-PET in gray matter. 
The FDG-PET results from the current study are consistent with previous FDG-PET 
studies that have shown reduced glucose metabolism in subjects with Alzheimer 
disease.28,45 Reduced glucose metabolism is also observed in the posterior cingulate, 
temporal, parietal lobes and later the frontal lobe.28,46 Mosconiet. al.47 showed that 
glucose metabolism in the hippocampus and the entorhinal cortex is also reduced in the 
preclinical stage of Alzheimer disease. In addition, Jagust et. al.48 has demonstrated that 
medial temporal and parietal glucose metabolism predicts cognitive decline. Glucose 
consumption measured by FDG-PET is also linearly associated with neuronal activity.49 
Therefore glucose consumption is considered an important biomarker in the detection of 
presymptomatic Alzheimer disease.50 
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A few RS-fMRI studies have also examined functional network activity in healthy 
subjects compared to people with Alzheimer disease. Seed based analysis studies17,18 
showed decreased functional connectivity (FC) in the medial temporal cortex, prefrontal 
cortex, precuneus, posterior cingulate, hippocampus, and thalamus in people with 
Alzheimer disease. Similar studies using ICA methods demonstrated reduced FC in 
precuneus, posterior cingulate, and parietal lobe in amnestic mild cognitive impairment 
(aMCI) subjects51 while Zhou et. al.52 showed decreased FC in the default mode network 
including the hippocampus and the medial temporal lobe in Alzheimer disease subjects. 
Therefore, functional connectivity measured by RS-fMRI has shown potential as a 
biomarker for dementia diagnosis. The observed positive correlation between the newly 
defined biomarker of neuronal activity measured by RS-fMRI and the MMSE score 
suggest that this biomarker is also related to cognitive function and performance. 
Furthermore, the positive association between neuronal activity measured by RS-fMRI 
and Aβ1-42provides a direct link to disease pathology.  
The new RS-fMRI metric related to brain activity showed different regional 
differences between NEC and Alzheimer disease subjects than that observed with FDG-
PET. Previous studies have found that cerebral blood flow is closely coupled with brain 
metabolism,53,54 and that both are decreased in people with Alzheimer’s disease.55-59 
Previous studies have also shown that there is an association between the resting brain 
activity and resting brain metabolism.60 The strong correlation observed between RS-
fMRI measured gray matter activity and FDG-PET measured glucose consumption in the 
current study is consistent with the notion that glucose metabolism is tightly coupled to 
the RS-fMRI measured brain activity. This result is also consistent with a recent study by 
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Aiello et. al.61 who showed a voxel-wise relationship between functional connectivity 
maps from RS-fMRI and glucose uptake measured by simultaneous FDG-PET in healthy 
subjects. Another recent study by Nugent et. al.62 demonstrated that the correlation 
between functional connectivity maps derived from RS-fMRI and glucose metabolism 
measured by FDG-PET was lower in temporal lobe epilepsy patients compared to control 
subjects. 
The group differentiation accuracy achieved using the brain activity metric in the 
accumbens measured by RS-fMRI was lower than that found when using FDG-PET 
measured glucose metabolism in the hippocampus (0.85). However, when combining 
hippocampal volume with brain activity from RS-fMRI in the hippocampus, the 
classification accuracy increased to 0.80, which is comparable to the FDG-PET results 
and significantly greater than using hippocampal volume alone.  The specificity achieved 
when using the combined MRI-based measurements (0.89) was also greater than that 
achieved by FDG-PET and hippocampal volume alone.  These results suggest that the 
combination of these MRI-based features could help to discriminate between healthy 
subjects and people with AD. 
This proof of concept study demonstrates that decreased resting-state brain activity is 
associated with decreased brain glucose metabolism in mild Alzheimer disease. 
Furthermore, we demonstrated group classification based on a first-order textural feature 
(standard deviation) of the RS-fMRI neuronal signal. It is noteworthy that when using a 
non-linear transformation (square root) of the resting-state signal (data not shown), group 
differences were not observed. There are several limitations of the current study that must 
be mentioned.  First, the sample size was limited by the availability of subjects with both 
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ten-minute RS-fMRI data and FDG-PET.  Regardless, the new metric was still able to 
differentiate between NEC and mild Alzheimer disease groups. Another limitation of this 
study is that we did not perform gray atrophy correction for either the RS-fMRI of FDG-
PET signal changes.  Therefore gray matter volume reduction in the hippocampus may 
partly explain the reduced RS-fMRI and FDG-PET measured brain activity.  However, 
Mosconi et. al.63 showed FDG-PET measured hypometabolism in the hippocampus 
despite atrophy correction in hippocampus. Gray matter atrophy measurements in the 
current study did show significant differences in the hippocampus between the two 
groups. However a classification model that included both the hippocampal volume and 
RS-fMRI brain activity showed an improved result to classification using either metric 
alone. Therefore, including this straightforward measurement of neuronal activity by RS-
fMRI with existing markers of neurodegeneration may increase the reliability of 
detecting Alzheimer’s disease. Future studies will evaluate the potential to identify 
people with mild cognitive impairment that progress to AD and whether this metric 
shows improvement following treatment.  
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Chapter 4: Combining Measures of Gait and Cognition to 
Predict Hippocampal Atrophy in Mild Cognitive Impairment 
 
The work presented in this chapter is in preparation for submission for publication. 
 
Samaneh Kazemifar, Manuel Montero-Odasso, and Robert Bartha 
 
 
 
4.1 Introduction 
 
Mild cognitive impairment (MCI) is defined as a transitional stage between normal 
aging and dementia1 and is clinically characterized by changes over time in distinct 
cognitive domains including: memory, executive function, attention, language and 
visuospatial skills. MCI is categorized into four types based on the presence of memory 
impairment and/or cognitive impairment in single or multiple domains.2,3 MCI subjects 
have a higher risk (10-15% per year) of progressing to Alzheimer’s disease compared 
with age-matched controls.4 Previous cross sectional group studies have shown reduced 
hippocampal volume,5,6 worse gait performance,7-9 as well as worse cognitive10,11 and 
memory performance in people with MCI.  However it is well known that some people 
with MCI remain stable or improve over time, while others decline.  Hippocampal 
atrophy in particular has evolved into an objective biomarker associated with cognitive 
decline and dementia.12,13 The overall objective of this study was to determine whether 
measures of gait and cognitive performance could be combined to predict hippocampal 
atrophy in people with MCI.  
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There is a strong rationale to combine measures of cognition and gait to predict 
progression to dementia.  Cognitive decline has been associated with a risk of falls,14-16 
which may also involve physiological dysfunction including impaired balance, slowed 
reaction time, muscular weakness and gait decline.17,18 Executive function is an important 
component of cognition and is referred to as the ability to control, remember, monitor, 
and organize information.19 Impairment of executive function with age has been 
correlated with changes in the frontal lobe and is consistently associated with an 
increased risk of falls.16 In addition, impairment in executive function is associated with 
poor balance, gait, and decline in physical performance.20,21 
Assessment of gait can include a single gait task or a dual gait task, which 
involves combined walking and simultaneous performance of a cognitive task. Previous 
studies in MCI subjects have also shown decrease gait velocity8,9 and increased stride 
time variability22 in gait analyses. Recently, a dual task gait analysis showed increased 
gait variability and decreased walking speed in MCI subjects compared to healthy 
controls when the dual task complexity increased.23 Similarly, Muir et. al.24 showed 
increased gait variability and decreased walking speed in AD subjects and people with 
MCI compared to a healthy group during dual task.  
There is also a potential relationship between specific cognitive domains and gait 
measurements. For example, there was an association between decreased gait speed and 
working memory in MCI subjects;7 and an inverse correlation between gait variability 
and executive performance in older adults25 and subjects with AD.26 Dual task 
performance has also been associated with decreased executive function.27 Therefore, 
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single and dual-task gait measurements can be considered a motor signature of MCI and 
may be a biomarker of cognitive decline.28 
Previous studies have also evaluated structural brain changes associated with gait and 
cognitive impairment in older adults and MCI subjects. Regional brain atrophy of the 
hippocampus was associated with decreased stride length in older adults29 and correlated 
with increased stride time variability.30 In addition, Palm et. al.31 found that ventricle 
enlargement was associated with decreased gait speed and cognitive decline in older 
adults. Another study showed that the temporal horn of the ventricle increased with stride 
time variability in older adults32 and that the primary motor cortex volume was correlated 
with gait performance in MCI subjects.33 Other regions of cortical atrophy have also been 
associated with gait decline including the prefrontal cortex, which was associated with 
decreased gait velocity,34 and the sensorimotor and frontoparietal cortex, which were 
associated with decreased stride length.35 
In summary, there are established associations between cognition and gait, brain 
atrophy and gait, as well as brain atrophy and cognition. In addition, hippocampal 
atrophy is an established biomarker of Alzheimer’s disease progression.  However it is 
unknown whether measure of gait performance or cognition can predict hippocampal 
atrophy in people with MCI.  Therefore, the objective of this study was to determine 
whether combined measures of gait and cognition could predict hippocampal atrophy 
over 18 months in people with amnestic MCI. 
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4.2 Methods 
4.2.1 Study population 
The ‘Gait and Brain Study’ in London, Ontario, Canada was approved by the 
University of Western Ontario Health Sciences Research Ethics Board. Cross-sectional 
and longitudinal neuropsychological tests, gait assessments, and magnetic resonance 
(MR) images were obtained from 22 people with MCI who were 65 years and older. 
Subjects were excluded if they were diagnosed with another type of neurologic disorder 
(e.g. Parkinson disease), or a medical or psychiatric disorder (e.g. stroke and depression), 
were taking medication (e.g. benzodiazepines) that might affect cognition, had a 
musculoskeletal disorder (e.g. osteoarthritis) or a disability that prevented walking 
independently, or had a hip/knee replacement that affected gait performance.  Participants 
were also excluded if they had metal implants or claustrophobia that were incompatible 
with 3T MRI, and were not fluent in English. Complete data sets for 22 MCI subjects 
were available at both baseline and 18 month and were used for this study. 
 
4.2.2 Cognitive Measures 
Global cognition was assessed using the mini mental state examination36 (MMSE) 
and the Montreal cognitive assessment10 (MoCA). All participants were also assessed 
using a battery of neuropsychological tests to evaluate different cognitive domains: 
episodic memory (Rey Auditory Verbal learning Test37 (RAVLT)), verbal 
comprehension and working memory (Letter numbering test38), executive function (Trail 
Making Test B39,40), and attention and processing speed (Trail Making Test A,40 Digit 
Span Test forward and backward41). We used standard diagnostic criteria for amnestic 
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MCI (impairment in episodic memory without other cognitive impairment) and MCI 
(impairment only in other cognitive domains).  To increase the specificity of diagnosis a 
cut off of 1.5 SD below the age-adjusted means was used on cognitive domains (on at 
least two neuropsychological tests in one of the five cognitive areas). Subjects with MCI 
did not meet the diagnostic criteria for Alzheimer disease. Cognitive testing was 
performed at baseline and repeated at six-month intervals until 18 months. 
 
4.2.3 Gait Analysis 
Gait performance was assessed using a computerized walkway with embedded 
pressure sensors (GAITRite®, 600 x 64 x 1 cm, active electronic surface area 792 x 610 
cm, with a total of 29952 pressure sensors, scanning frequency 60 Hz, software version 
3.8, CIR Systems). The GAITRite® system is a reliable tool for gait analysis that has 
been validated for several gait protocols including for assessments of gait velocity and 
variability.42 The single-task and dual task trials were performed in random order to 
minimize the error of learning. To avoid acceleration and deceleration errors, 
participant’s started 1m before reaching the electronic walkway and ended their walk 1m 
beyond it, consistent with validated protocols.42,43 During single-task conditions, 
participants walked at their usual pace. In dual-task conditions, participants walked in 
combination with three different cognitive tasks performed aloud: counting backwards by 
1 from 100, subtracting serial seven from 100, and naming animals. Both simple and dual 
task conditions were used to evaluate the following gain parameters: gait velocity (cm/s), 
gait stride time (s), gait stride time variability (a.u.) (standard deviation of stride 
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time/mean stride time), step time (s), stride length, step length, double support time (s), 
swing time (s), stride width, step width, stride velocity, cadence, step time coefficient of 
variation, stride length coefficient of variation, step length coefficient of variation, double 
support time coefficient of variation, swing time coefficient of variation, stride width 
coefficient of variation, step width coefficient of variation, and stride velocity coefficient 
of variation. Gait assessment occurred at baseline and again at 18 months. 
 
4.2.4 MRI 
MR images were acquired to measure hippocampal atrophy using a 3T Magnetom 
Prisma MRI scanner with a Siemens (Erlangen, Germany) 64-channel head/neck coil. 
Structural T1-weighted images were obtained using a sagittal 3D magnetization-prepared 
rapid acquisition with a gradient echo (MP-RAGE) sequence: flip angle= 9°, TE= 2.9ms, 
TR= 2300ms, TI= 900 ms, FOV= 256 x 240 mm2, matrix, 256x240 pixel size, 
1mm×1mm×1.2mm; 160 slices, total duration= 9.25 min). All imaging was performed at 
baseline and repeated at 18 months. 
 
4.2.5 Medial Temporal Lobe Atrophy 
The 3D T1-weighted MR images were used to segment the medial temporal lobe 
(MTL) at baseline and 18 month follow-up using the in-house software called EXACT as 
previously described in detail44 and found in Chapter 2 of this thesis. The MTL volume 
included primarily the hippocampus, the amygdala, fibers associated with the amygdala, 
and the parahippocampal gyrus. The FreeSurfer software (version 5.3.0) was also used to 
segment subcortical regions including the hippocampus, the lateral ventricle, and the 
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temporal horn of the lateral ventricle. FreeSurfer (http://surfer.nmr.mgh.harvard.edu/) is 
free automated software for processing and analyzing human brain structural and 
functional MR images. Briefly, the volumetric processing included removal of non-brain 
tissue,45 Talairach transformation, and segmentation of the subcortical white matter and 
deep gray matter volumetric structures.46,47 All brain volumes were normalized to the 
intracranial volume obtained with FreeSurfer to obtain a volume ratio (VR). In addition, 
the change in volume (ΔV) over 18 months was also measured for each structure. 
 
4.2.6 Feature extraction 
An overview of the feature extraction method is shown in Figure 4.1.  In this study, 
all measurements including gait, neuropsychological, and brain volumetrics are presented 
in an n x m data matrix, where n is the number of subjects and m is the number of 
measurements. A principle component analysis48,49 (PCA) was used to extract principle 
components (PCs) or eigenvectors that explained the maximum variance of the data 
matrix. We selected the PCs that had eigenvalues greater than one as previously 
described.50 Then, the data matrix (n x m) was multiplied with PCs (m x v) to produce 
projection data (n x v), where v is the number of eigenvalues> 1. A machine learning 
method was then applied to predict hippocampal atrophy (two groups) using the 
projection data from the PCA. Here, the subjects were divided into two groups (stable 
and decliner) based on the change in volume (ΔV) of the MTL measured by EXACT.  
Using this definition, 14 subjects were considered stable and 8 subjects showed MTL 
atrophy.  
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Figure 4.1 Schematic of the analysis pipeline 
Variables include gait, neuropsychological, and anatomical measurements at baseline and over 18 
months. The PCA method is used for feature extraction and is followed by the SVM classifier. 
 
PCA was performed in SPSS (Statistical Package for the Social Sciences, version 24). 
Table 4.1 shows the demographic information for all subjects and includes a summary of 
the anatomical, gait, and neuropsychological measurements at baseline and 18 months.  
Two separate analyses were performed. The first analysis incorporated only baseline 
measurements to assess prediction ability. The second analysis incorporated only changes 
in measurements over 18 months to assess associations. In the analysis of the baseline 
measurements, the input data (22 subjects x m variables) included two classes: the stable 
MCI group (14 participants) and the decliner MCI group (8 participants). All m gait, 
neuropsychological, and MRI measures were also included. For the analysis of the 
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changes over 18months the input data (22 subjects x m variables) incorporated only the 
neuropsychological and gait measurements. The PCA extracted the most influential 
components associated with the baseline and 18-month change measurements. The 
projection of the PCA (22 subjects x v) using the baseline data and the projection of the 
PCA (22 subjects x v) using the 18 months changes were passed into the support vector 
machine.  
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Table 4.1 Subject demographic 
Neuropsychological, gait, and anatomical measurements are provided for all participants.  
Hippocampus, temporal horn and lateral ventricle volumes are normalized to intracranial volume. 
The first value shows the mean and the parentheses show the standard error of mean (SEM). *P 
value<0.05 (paired, two tailed) 
 
 MCI MCI P 
value 
Time  Baseline 18 month  
N 22 22  
Age (years) 73.0 (1.2) 74.5 (1.2)  
Education (years) 13.2 (0.5) 13.2 (0.5)  
Sex (Female) 6/22 6/22  
    
Neuropsychological Test Scores    
MMSE 29.0 (0.3) 28.0 (0.4) 0.09 
MOCA 25.0 (0.6) 25.1 (0.5) 0.7 
Trail A 41.7 (3.6) 37.1 (3.3) 0.1 
Trail B 110.2 (14.3) 111.0 (17.4) 0.9 
RAVLT  5.3 (0.6) 6.5 (0.5) 0.04* 
Letter Numbering 8.2 (0.5) 8.3 (0.6) 0.9 
Digit Forward 11.1 (0.4) 11.0 (0.4) 0.8 
Digit Backward 7.4 (0.5) 7.1 (0.6) 0.6 
    
Single Task Gait Measures    
Usual Gait Velocity (cm/s) 117.1 (4.4) 115.1 (4.0) 0.6 
Usual Gait Stride Time (ms) 1142.3 (24.6) 1128.2 (21.3) 0.6 
Usual Gait Stride Time Variability (a.u.) 2.4 (0.3) 4.2 (1.4) 0.2 
    
Dual Task Gait Measures    
Counting Gait Velocity (cm/s) 114.1 (6.0) 108.6 (4.6) 0.3 
Counting Gait Stride Time (ms) 1200.4 (36.8) 1193.3 (23.1) 0.8 
Counting Gait Stride Time Variability (a.u.) 3.3 (0.4) 2.8 (0.3) 0.3 
Serial 7s Gait Velocity (cm/s) 99.2 (7.4) 96.8 (5.3) 0.7 
Serial 7s Gait Stride Time (ms) 1365.8 (60.0) 1315.3 (54.3) 0.4 
Serial 7s Gait Stride Time Variability (a.u.) 6.3 (1.1) 4.5 (0.8) 0.2 
Naming Animal Gait Velocity (cm/s) 103.5 (6.0) 99.1 (5.5) 0.4 
Naming Animal Gait Stride Time (ms) 1291.0 (41.5) 1281.5 (47.1) 0.8 
Naming Animal Gait Stride Time Variability (a.u.) 3.7 (0.5) 3.1 (0.2) 0.3 
    
MRI Measures    
Hippocampus Volume Ratio 0.0049 (0.0001) 0.0048 (0.0001) 0.6 
Temporal Horn Ventricle Volume Ratio  0.001 (0.0001) 0.001 (0.0001) 0.5 
Lateral Ventricle Volume Ratio  0.02 (0.002) 0.02 (0.002) 0.6 
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4.2.7 Support vector machine 
The support vector machine (SVM), a classifier that finds a separating hyperplane 
between two classes (groups), was performed in Matlab (version R2010a, with linear 
kernel function, and least square method).51-53 We used the projection baseline data (22 
subjects x v) to discriminate stable and decliner classes (groups). Similarly, the projection 
18 month change data (22 subjects x v) were used to classify stable and decliner classes 
(groups). In this study, the leave one out test (LOOT) cross-validation technique was 
performed to train a given labeled training set and unused data were validated to identify 
its label. The training and testing phase were preformed individually for baseline and 18 
months change measurements. To evaluate the performance of the SVM classifier, the 
accuracy, sensitivity, and specificity (statistical measurements) were calculated. Here, 
true positive indicates decliners that were correctly identified as decliner class. False 
positive is the number of stable subjects incorrectly identified as the decliner class. True 
negative is the number of stable subjects correctly identified as stable subjects. False 
negative is the number of decliners incorrectly identified as stable subjects. Therefore, 
accuracy refers to the proportion of true results (both true positive and true negative) over 
the total number of subjects. Sensitivity indicates the proportion of subjects correctly 
detected as decliners (number of true positive over number of true positive and number of 
false negative). Specificity shows the proportion of subjects correctly identified as stable 
(number of true negative over number of true negative and number of false positive). 
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4.2.8 Statistical analysis 
Prism GraphPad (Prism, version 6.00; GraphPad Software, San Diego, CA) and Matlab 
toolbox (version R2010a) were used for the statistical analyses. A one-way ANOVA was 
used to compare cognitive, gait, and neuroimaging measurements between the stable and 
decliner MCI groups (p<0.05 considered significant). Individual measurements were also 
compared at baseline and 18 months follow-up using a repeated measures t-test with two 
tailed.  Individual measurements between the Decliner and Stable MCI groups were also 
compared using ANOVA with Bonferroni correction.  Associations between cognitive 
tests and imaging measures were evaluated by linear regression with Pearson correlation 
coefficients with p <0.05 considered significant.   
 
4.3 Results 
Table 4.1 summarizes subject demographic information as well as summative 
measures at baseline and 18 month follow-up. Although gait measurements consisted of a 
total of 74 variables (Table 4.8) only the twelve most common are reported in Table 4.1 
and included in the one-way ANOVA comparison.  The one-way ANOVA indicated that 
was a significant overall difference between baseline and 18 months follow-up when 
incorporating the anatomical, neuropsychological, and gait measurements (p<0.0001). 
However follow-up repeated measures comparisons (Bonferroni’s corrected for 23 
comparisons) failed to identify specific variables that were different between the two 
groups. Interestingly, there was a significant correlation between the change in MTL 
volume and change in RAVLT over 18 months across all subjects (Figure 4.2).  There 
were no other correlations between changes in MTL volume and cognitive measures. 
 
 
137 
 
 
Figure 4.2 Association between change in RAVLT and the change in MTL volume 
over 18 months 
(r= 0.53, p=0.01) Subjects were considered stable or in decline based on the sign of the MTL 
volume changes. Data for 19 subjects is included because 3 subjects did not have RAVLT at one 
time point. 
 
Tables 4.2 and 4.3 summarize the demographic information as well as important gait, 
neuropsychological, and anatomical measurements for the stable and decliner groups at 
baseline and 18 months. A one-way ANOVA indicated that there was a significant 
difference between the stable and decliner groups in all measurements at baseline 
(p<0.0001) and in the changes observed over 18 months (p<0.0001). However, 
examining individual measurements, there were no significant differences between these 
groups at baseline or over 18 month following Bonferroni correction for 23 comparisons. 
Tables 4.4 and 4.5 show the accuracy, sensitivity, and specificity obtained when using the 
anatomical, neuropsychological, and gait measurements or combinations of these 
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measurements at baseline and after 18 months. In the analysis of the baseline data, gait 
measures had the highest overall accuracy (0.74), sensitivity (0.66), and specificity (0.75) 
for identifying hippocampal atrophy. Adding baseline brain volumetrics or 
neuropsychological assessments did not improve the overall accuracy, sensitivity, and 
specificity of the gait measurements. While, in the 18 months change analysis, the 
neuropsychological measurements achieved the highest overall accuracy (0.72), 
sensitivity (0.32), and specificity (0.89). The addition of gait measurements did not 
improve the overall accuracy, sensitivity, and specificity (Table 4.5).   
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Table 4.2 Subject demographics of the two groups at baseline 
The neuropsychological, gait, and anatomical measurements at baseline are shown in the 
8decliner and 14 stable subjects. The first value shows the mean and the parentheses show the 
standard error of the mean (SEM). *P value<0.05 (unpaired, two tailed) 
 
 Decliner MCI Stable MCI P 
value 
Time  Baseline Baseline  
N 8 14  
Age (years) 70.8 (1.5) 74.1 (1.6)  
Education (years) 14.2 (1.0) 12.6 (0.6)  
Sex (% Female) 25% 29%  
    
Neuropsychological Test Scores    
MMSE 29.1 (0.5) 28.8 (0.4) 0.6 
MOCA 25.6 (0.9) 24.5 (0.8) 0.4 
Trail A 47.0 (8.9) 38.7 (2.7) 0.2 
Trail B 122.3 (37.1) 103.3 (8.8) 0.5 
RAVLT  5.6 (1.6) 5.1 (0.6) 0.7 
Letter Numbering 7.5 (0.6) 8.7 (0.7) 0.2 
Digit Forward 10.5 (0.7) 11.5 (0.5) 0.2 
Digit Backward 6.5 (0.8) 7.9 (0.6) 0.05 
    
Single Task Gait Measures    
Usual Gait Velocity (cm/s) 123.3 (8.9) 113.6 (4.6) 0.3 
Usual Gait Stride Time (ms) 1125.2 (57.2) 1152.3 (22.0) 0.6 
Usual Gait Stride Time Variability (a.u.) 2.7 (0.6) 2.3 (0.3) 0.6 
    
Dual Task Gait Measures    
Counting Gait Velocity (cm/s) 122.6 (11.1) 109.2 (6.8) 0.2 
Counting Gait Stride Time (ms) 1157.8 (60.2) 1224.7 (46.1) 0.3 
Counting Gait Stride Time Variability (a.u.) 3.0 (0.4) 3.5 (0.6) 0.5 
Serial 7s Gait Velocity (cm/s) 105.9 (16.1) 95.3 (7.3) 0.5 
Serial 7s Gait Stride Time (ms) 1367.3 (132.4) 1364.9 (60.0) 0.9 
Serial 7s Gait Stride Time Variability (a.u.) 5.3 (1.6) 6.9 (1.4) 0.4 
Naming Animal Gait Velocity (cm/s) 112.7 (12.0) 98.1 (6.2) 0.2 
Naming Animal Gait Stride Time (ms) 1225.0 (71.2) 1328.7 (49.3) 0.2 
Naming Animal Gait Stride Time Variability (a.u.) 3.2 (0.8) 4.0 (0.7) 0.5 
    
MRI variables    
Hippocampus Volume Ratio  0.0048 (0.0001) 0.0049 (0.0002) 0.7 
Temporal Horn Ventricle Volume Ratio  0.001 (0.0002) 0.0009 (0.0001) 0.5 
Lateral Ventricle Volume Ratio  0.02 (0.003) 0.02 (0.003) 0.2 
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Table 4.3 Subject demographics of the two groups showing 18-month changes 
The changes in the neuropsychological, gait, and anatomical biomarkers are compared for 
the8decliner and 14 stable subjects. First value shows the mean and parentheses show the 
standard error of the mean (SEM). *P value<0.05 (unpaired, two tailed) 
 
 Decliner MCI Stable MCI P 
Value 
Time  Δ18 months Δ18 months  
N 8 14  
    
Neuropsychological Test Scores    
MMSE Changes -1.0 (0.6) -0.8 (0.6) 0.8 
MOCA Changes -0.1 (0.9) 0.4 (0.6) 0.6 
Trail A Changes -10.1 (4.7) -1.4 (1.8) 0.03* 
Trail B Changes 16.0 (18.3) -8.0 (8.4) 0.1 
RAVLT Changes 1.3 (0.8) 1.1 (0.8) 0.8 
Letter Numbering Changes 1.3 (0.8) -0.7 (0.4) 0.02* 
Digit Forward Changes -0.2 (0.6) -0.07 (0.5) 0.8 
Digit Backward Changes 0.7 (0.7) -0.8 (0.4) 0.054 
    
Single Task Gait Measures    
Usual Gait Velocity (cm/s) Changes -6.0 (8.0) 0.2 (3.4) 0.4 
Usual Gait Stride Time (ms) Changes -4.2 (48.2) -19.8 (28.1) 0.7 
Usual Gait Stride Time Variability (a.u.) Changes -0.2 (0.8) 2.8 (2.3) 0.3 
    
Dual Task Gait Measures    
Counting Gait Velocity (cm/s) Changes -10.1 (8.3) -2.7 (4.6) 0.4 
Counting Gait Stride Time (ms) Changes -10.8 (34.2) -4.8 (44.6) 0.9 
Counting Gait Stride Time Variability (a.u.) Changes -0.1 (0.7) -0.8 (0.6) 0.5 
Serial 7s Gait Velocity (cm/s) Changes -3.1 (10.5) -2.0 (5.1) 0.9 
Serial 7s Gait Stride Time (s) Changes -101.0 (109.6) -21.0 (65.1) 0.5 
Serial 7s Gait Stride Time Variability (a.u.) Changes -1.0 (2.0) -2.3 (1.0) 0.5 
Naming Animal Gait Velocity (cm/s) Changes -7.6 (6.2) -2.4 (4.0) 0.4 
Naming Animal Gait Stride Time (ms) Changes -16.2 (36.4) -5.5 (44.3) 0.8 
Naming Animal Gait Stride Time Variability Changes (a.u.) -0.2 (1.2) -1.0 (0.7) 0.5 
    
MRI variables    
Hippocampus Volume Changes (mm3) -201.3 (92.3) 3.9 (181.6) 0.4 
Lateral Ventricle Volume Changes (mm3) 934.1 (500.6) 3590.6 (991.3) 0.06 
Temporal Horn Ventricle Volume Changes (mm3) 92.7 (111.6) 198.8 (79.2) 0.4 
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Table 4.4 Summary of accuracy, sensitivity, and specificity for the stable and 
decliner groups based on the baseline measurements after PCA projection 
 
  
SVM_ linear Baseline 
 
# PCs 
 
Accuracy 
 
Sensitivity 
 
Specificity 
Neuropsychological 2 0.70 0 1 
Gait 12 0.74 0.66 0.75 
MRI  1 0.63 0 0.86 
Gait + Neuropsychological 13 0.60 0.27 0.70 
Gait + MRI 13 0.70 0. 43 0.85 
Neuropsychological + MRI 4 0.73 0 1 
Gait + Neuropsychological + MRI 14 0.60 0.30 0.76 
 
 
Table 4.5 Summary of the accuracy, sensitivity, and specificity for the stable and 
decliner groups based on the changes in measurements over 18 months after PCA 
projection 
 
  
SVM_ linear Δ18 months 
 
# PCs 
 
Accuracy 
 
Sensitivity 
 
Specificity 
Neuropsychological 4 0.72  0.32 0.89 
Gait 12 0.64 0.30 0.73 
Gait + Neuropsychological 15 0.69 0.30 0.81 
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To identify the measurements that were most influential in the PCA, a heat map was 
used to show the coefficients for each variable in the PCs that had eigenvalues greater 
than one.  Figure 4.3 shows the heat map associated with the gait measurements at 
baseline, while Figure 4.4 shows the heat map associated with the neuropsychological 
measures over time.  These are shown because these measures were found to have the 
greatest accuracy, sensitivity, and specificity. The color in the heat map shows the 
contribution weight of the measurement in the principle component. A hot color shows a 
higher coefficient and a cold color illustrates a lower coefficient. Each coefficient shows 
the proportion of the eigenvalue corresponding to each principle component 
(eigenvalue= (coefficent!)). The proportion of the variance is accounted for each PC by 
var = eigenvalue #  variables. Therefore, the first PC includes the maximum proportion 
of variance in the data and the accumulation of all variance is equal to one. Table 4.6 
provides the ten highest numerical coefficients associated with the first PC in the heat 
map shown in Figure 4.3, while Table 4.7 provides the 4 highest numerical coefficients 
associated with the first PC in the heat map shown in Figure 4.4. In the baseline analysis, 
the gait velocity, and stride velocity during single and dual tasks were the most important 
measurements.  Examining changes over 18 months, the digit span test forward and 
backward tests had the highest predictive values. 
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Figure 4.3 Heat map to identify the most important baseline measurements 
contributing to each principle component (PC)   
Each row indicates a different measurement with the measurement number identified on the left 
corresponding to the measurement numbers in Table 4.8. The colors indicate the coefficient and 
provide the contribution weight of the measurement in each principle component. 
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Figure 4.4 Heat map to identify the most important 18 months change 
measurements contributing to each principle component (PC)   
Each row indicates a different measurement with the measurement number identified on the left 
corresponding to the measurement numbers in Table 4.9. The colors indicate the coefficient and 
provide the contribution weight of the measurement in each principle component. 
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Table 4.6 Predictive variables of gait measurements to distinguish between stable 
and decliner groups in overall 22 subjects based on baseline values 
The coefficient shows the contribution weight of the variable in first principle component.  
 
Dominant Variables Coefficient 
  
Single gait variables  
Usual gait velocity  -0.88 
Stride velocity -0.88 
  
Dual gait variables  
Counting gait velocity  -0.93 
Counting gait stride time  0.82 
Counting stride velocity -0.93 
Counting cadence -0.84 
  
Serial 7s velocity  -0.95 
Serial 7 stride velocity -0.95 
Serial 7 cadence -0.81 
  
Naming animals velocity -0.92 
Naming animals stride velocity -0.92 
 
 
 
Table 4.7 Predictive variables of neuropsychological measurements to identify stable 
and decliner groups in overall 22 subjects based on 18 months change values 
The coefficient shows the contribution weight of variable in first principle component. 
 
Dominant Variables Coefficient 
  
Neuropsychological  
MMSE -0.41 
Trail A -0.44 
Trail B 0.34 
Digit span test backward 0.76 
Digit span test forward 0.72 
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4.4 Discussion 
In this study, subjects with MCI were divided into two groups (stable and declining) 
based on MTL volume changes over 18 months. When incorporating all anatomical, gait, 
and neuropsychological measurements there was an overall significant difference 
between those identified as stable and those that declined. However, when comparing 
individual measurements between both groups, no significant differences were found 
following Bonferroni correction. The use of baseline gait measurements provided the 
greatest prediction accuracy of hippocampal atrophy over 18 months. Surprisingly, 
combining gait measurements with baseline neuropsychological measurements and brain 
volumetrics did not improve prediction accuracy. A potential explanation is that gait can 
be more sensitive to brain changes that cognitive testing in early stages of decline.54 This 
is supported by epidemiological evidence that shows that slowing gait precede cognitive 
decline in cognitively healthy individuals who progress to MCI.55 MTL volume changes 
were correlated with changes in the RAVLT. The significant association between 
changes in MTL volume and changes in RAVLT score is consistent with previous cross 
sectional studies.56,57 Since the RAVLT is an indicator of memory,58,59 it is expected to 
correlate strongly with hippocampal volume.   
PCA is a statistical technique used to reduce the number of dimensions without 
incurring a loss of information. To identify the most important measurements, the PCA 
method was applied to all baseline measurements and the changes in these measurements 
over 18 months. Using this approach, the baseline gait velocity and stride velocity during 
single and dual task had higher eigenvalue coefficients compared to other measures 
indicating that these measures explain more of the data variability than other measures.  
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This result is consistent with the finding that dysfunction of gait particularly in dual tasks 
co-occurs with cognitive functional decline in older adults even in the early stages of 
aging.7,54 Also, it has been suggested that dual task gait variables can be used as early 
markers for MCI diagnosis.60 
Following the PCA, the SVM classifier was applied to predict hippocampal atrophy 
using the projection data of the PCA. The baseline gait measures had the highest 
accuracy (0.74), sensitivity (0.66), and specificity (0.75) for predicting hippocampal 
atrophy. When examining changes over 18 months, the neuropsychological 
measurements achieved the high accuracy (0.72), sensitivity (0.32), and specificity 
(0.89). The changes over 18 months in the digit span test forward and backward had the 
greatest predictive values. Surprisingly, combining gait, neuropsychological, and even 
imaging measurements did not improve this classification.  Although there are no 
previous studies that combine measures of gait and neuropsychological testing to predict 
hippocampal atrophy, several other studies have examined the use of imaging and CSF 
measurements to improve classification accuracy between two groups. For example, 
Zhang et. al.61 used MRI, PET neuroimaging, and CSF measurements to classify between 
healthy, MCI and Alzheimer disease groups using data obtained from the ADNI database. 
They found high accuracy, sensitivity and specificity in classification between the healthy 
and Alzheimer disease groups when MRI, PET and CSF biomarkers were used. Another 
previous study62 used four groups including healthy, early MCI, late MCI and AD groups 
from the ADNI database to measure cortical and subcortical MRI volumes and 
neuropsychological tests.  They found the accuracy was 0.70 to distinguish early MCI 
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and late MCI using a combination of all variables; while it were 0.63 and 0.68 using 
neuropsychological tests and MRI variables. 
This study is unique in that we used hippocampal atrophy to classify subjects into 
stable and declining rather than neuropsychological test scores.  However, there are 
several limitations to this preliminary study that must be considered.  The first is the 
small sample size, particularly in the group that showed hippocampal volume atrophy. A 
future study should replicate these results in a larger sample.  Second, the changes 
observed in hippocampal volume were small, even over 18 months.  Some subjects 
increased slightly in volume, while others decreased.  Overall, on average there was no 
change in this group.  This observation suggests that a longer follow-up time may be 
needed to accurately determine which subjects are in decline.   
In conclusion, this study provides preliminary evidence of gait impairment in people 
with mild cognitive impairment who proceed to have hippocampal atrophy within 18 
months of follow-up.  The results provide a rationale to suggest that gait analysis could 
help to predict future hippocampal atrophy in people at risk to progress to dementia. 
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Table 4.8 Abbreviation: The number corresponds to the variable in Figure 4.2 
 
1 Usual	  Gait	  Velocity 
2 Usual	  gait	  stride	  time 
3 Usual	  gait	  stride	  time	  variability 
4 Step	  time 
5 Stride	  length 
6 Step	  length 
7 Double	  Support	  Time 
8 Swing	  Time 
9 Stride	  Width 
10 Stride	  Velocity 
11 Cadence 
12 Step	  time	  coefficient	  of	  variation 
13 Stride	  length	  coefficient	  of	  variation 
14 Step	  length	  coefficient	  of	  variation 
15 Double	  support	  time	  coefficient	  of	  variation 
16 Swing	  time	  coefficient	  of	  variation 
17 Stride	  width	  coefficient	  of	  variation 
18 Stride	  velocity	  coefficient	  of	  variation 
19 Counting	  gait	  velocity 
20 Counting	  gait	  stride	  time 
21 Counting	  gait	  stride	  time	  variability 
22 Counting	  Step	  time 
23 Counting	  Stride	  length 
24 Counting	  Step	  length 
25 Counting	  Double	  Support	  Time 
26 Counting	  Swing	  Time 
27 Counting	  Stride	  Width 
28 Counting	  Stride	  Velocity 
29 Counting	  Cadence 
30 Counting	  Step	  time	  coefficient	  of	  variation 
31 	  Counting	  Stride	  length	  coefficient	  of	  variation 
32 Counting	  Step	  length	  coefficient	  of	  variation 
33 Counting	  Double	  support	  time	  coefficient	  of	  variation 
34 Counting	  Swing	  time	  coefficient	  of	  variation 
35 Counting	  Stride	  width	  coefficient	  of	  variation 
36 Counting	  Stride	  velocity	  coefficient	  of	  variation 
37 Counting	  back	  total	  number 
38 Serial	  7s	  velocity 
39 Serial	  7s	  stride	  time 
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40 Serial	  7s	  stride	  time	  variability 
41 Serial	  7	  Step	  time 
42 Serial	  7	  Stride	  length 
43 Serial	  7	  Step	  length 
44 Serial	  7	  Double	  Support	  Time 
45 Serial	  7	  Swing	  Time 
46 Serial	  7	  Stride	  Width 
47 Serial	  7	  Stride	  Velocity 
48 Serial	  7	  Cadence 
49 Serial	  7	  Step	  time	  coefficient	  of	  variation 
50 Serial	  7	  Stride	  length	  coefficient	  of	  variation 
51 Serial	  7	  Step	  length	  coefficient	  of	  variation 
52 Serial	  7	  Double	  support	  time	  coefficient	  of	  variation 
53 Serial	  7	  Swing	  time	  coefficient	  of	  variation 
54 Serial	  7	  Stride	  width	  coefficient	  of	  variation 
55 Serial	  7	  Stride	  velocity	  coefficient	  of	  variation 
56 Total	  numbers	  counted	  backwards	  by	  7 
57 Naming	  animals	  velocity 
58 Naming	  animals	  stride	  time 
59 Naming	  animals	  gait	  stride	  time	  variability 
60 Naming	  animals	  Step	  time 
61 Naming	  animals	  Stride	  length 
62 Naming	  animals	  Step	  length 
63 Naming	  animals	  Double	  Support	  Time 
64 Naming	  animals	  Swing	  Time 
65 Naming	  animals	  Stride	  Width 
66 Naming	  animals	  Stride	  Velocity 
67 Naming	  animals	  Cadence 
68 Naming	  animals	  Step	  time	  coefficient	  of	  variation 
69 Naming	  animals	  Stride	  length	  coefficient	  of	  variation 
70 Naming	  animals	  Step	  length	  coefficient	  of	  variation 
71 Naming	  animals	  Double	  support	  time	  coefficient	  of	  variation 
72 Naming	  animals	  Swing	  time	  coefficient	  of	  variation 
73 Naming	  animals	  Stride	  width	  coefficient	  of	  variation 
74 Naming	  Animals	  Stride	  velocity	  coefficient	  of	  variation	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Table 4.9 Abbreviation: The number corresponds to the variable in Figure 4.3 
 
1 MMSE 
2 MoCA 
3 Trail	  A 
4 Trail	  B 
5 Digit	  Forward 
6 Digit	  Backward 
7 Letter	  Numbering 
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CHAPTER 5: Conclusion and Future work 
 
This chapter includes an overview of the thesis, a summary of the main contributions, 
and provides suggestions for further investigation and development. 
 
5.1 Overview and Summary 
The limitations of current tools for the pre-symptomatic diagnosis and monitoring of 
disease progression for Alzheimer disease (AD) provided the motivation for developing 
more sensitive biomarkers.  Such biomarkers could be used for early detection of AD and 
other related dementias, as well as monitoring disease progression and response to new 
treatments.  The monitoring of treatment effects is an area of particular need to hasten the 
development of more effective drugs that slow the progression of the disease.   
The preclinical or pre-symptomatic stage of AD is associated with pathological 
changes that begin 10-15 years before synaptic or neuronal loss result in cognitive 
decline and dementia. Therefore, new candidate drugs will be needed to intervene at an 
early stage of the disease to prevent brain damage and subsequent dementia. Currently, 
AD is diagnosed base on the results of a clinical examination and cognitive testing, but a 
clinical diagnosis can result in misclassification because a definitive biomarkers does not 
exist.1 Furthermore, clinical examination cannot detect pre-symptomatic AD and cannot 
measure the rate of disease progression.  
It is challenging to develop biomarkers for presymptomatic AD because changes in 
the brain are subtle. The ideal biomarker should reveal AD pathology, be reliable, be easy 
to measure, and be relatively inexpensive.2 Imaging methods including anatomical MRI, 
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PET, and functional MRI, which can assess regional/global structural and functional 
impairment have the potential to identify pathological changes associated with AD.  
One example of a widely studied anatomical measurement is hippocampal atrophy, 
which has been associated with memory loss in AD subjects.3 This anatomical 
assessment could be a suitable biomarker of the transition from normal cognition to mild 
cognitive impairment (MCI), and from MCI to AD. Due to inter-individual variation in 
the volume of anatomical structures, the change in volume of these structures is likely to 
be a more sensitive indicator of Alzheimer disease (AD) progression. Although several 
methods are available to measure brain volumes, improvements in speed and automation 
are required. We hypothesized that a highly reproducible measure of the change in MTL 
(ΔMTL) volume would be a sensitive marker of Alzheimer disease progression.  In 
Chapter 2 of this thesis, we described a novel, fully automated, fast, and reliable 
segmentation method designed to measure the change in MTL volume including 
primarily hippocampus over time in the same subject. The novel segmentation approach 
presented here combined a multiple atlas-based registration method to define the tissue 
region of interest, a level set algorithm to refine the shape of the medial temporal lobe, 
and registration of baseline images to follow up images to increase measurement 
precision. The measured volume change in the MTL is the difference between the 
baseline and follow-up volume. The automated segmentation approach developed in this 
study represents an expedient atrophy change in tissue (EXACT) measurement of the 
brain. Baseline and 24 month 3D T1-weighted images from the Alzheimer Disease 
Neuroimaging Initiative (ADNI) were randomly selected for 50 normal elderly controls 
(NEC), 50 subjects with mild cognitive impairment (MCI) and 50 subjects with AD to 
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test the algorithm. A manual segmentation of the hippocampus showed that the 
hippocampus accounts for only about 40% of the total volume of interest included by the 
EXACT method. The average hippocampal volume change measured using the EXACT 
method was significantly smaller than that measured using the FreeSurfer software 
package in NEC (p=0.03), MCI (p=0.001), and AD (p=0.003). However, the EXACT 
method showed a significant difference in MTL volume change between all three groups 
while the FreeSurfer measurements did not detect a difference between the MCI and AD 
subject groups. The novel segmentation approach we developed is fully automated and 
provides a robust marker of brain atrophy that showed different rates of atrophy over two 
years in NEC, MCI, and AD groups. The MTL atrophy measures also correlated with 
decline in cognitive performance. 
In Chapter 3, the goal was to define a novel biomarker of neuronal activity based on 
a first-order textural feature of the resting state functional-MRI (RS-fMRI) signal. The 
hypothesis was that the fluctuation of the magnitude of the blood oxygen level dependent 
(BOLD) signal as a function of time is related to neuronal activity and therefore would 
also correlate with FDG-PET measures of glucose metabolism. Furthermore, we 
examined the association between the fluctuation magnitude of the neuronal derived RS-
fMRI signal and FDG-PET. In this study, after pre-processing the RS-fMRI signal, an 
independent component analysis (ICA) method was applied to the RS-fMRI, followed by 
template matching to identify neuronal components (NC). A brain activity map was 
constructed based on the variation of the RS-fMRI signal from these NC. The 
standardized glucose uptake values of several brain regions relative to the cerebellum 
(SUVR) were also measured from partial volume corrected FDG-PET images. We 
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studied 15 normal elderly controls (NEC) and 15 probable Alzheimer disease (AD) 
subjects from the AD Neuroimaging Initiative (ADNI) database. In addition, the mini 
mental state examination (MMSE) score, CSF biomarkers including total Tau protein 
(Tau), phosphorylated Tau protein (P-Tau) and amyloid-β (Aβ1-42) were obtained for all 
subjects. Comparing the AD and NEC groups, the mean brain activity metric was 
significantly lower in the accumbens, while the glucose SUVR was significantly lower in 
the amygdala and hippocampus. There was also a significant correlation between the 
MMSE score and brain activity measured using RS-fMRI in several brain regions. 
Similarly there was a significant correlation between CSF Aβ1-42 levels and the RS-fMRI 
measured brain activity in several brain regions. We found a pixel-by-pixel association 
between the RS-fMRI measured brain activity in gray matter and the rate of glucose 
metabolism measured using FDG-PET (r=0.77 ± 0.04 for the NEC group and r=0.73 ± 
0.03 for the Alzheimer disease group). This proof of concept study demonstrated that 
decreased resting-state brain activity is associated with decreased brain glucose 
metabolism in mild Alzheimer disease. We demonstrated differences in brain activity 
measured by RS-fMRI in effect establishing this measurement as a new potential 
biomarker of Alzheimer’s disease.  However, future longitudinal studies will be required 
to determine its utility in combination with existing markers of neurodegeneration to 
determine whether this measurement has a role in the early detection of Alzheimer’s 
disease. 
In chapter 4, we examined the relationship between gait and hippocampal atrophy in 
people with MCI.  There are established associations between cognition and gait, brain 
atrophy and gait, as well as brain atrophy and cognition in subjects with MCI. In addition, 
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hippocampal atrophy is an established biomarker of Alzheimer’s disease progression.  
However it is unknown whether measures of gait performance or cognition can predict 
hippocampal atrophy in people with MCI.  The purpose of this study was to determine 
which combination of measurements could best predict hippocampal atrophy over 18 
months in people with MCI. We hypothesized that the combination of 
neuropsychological and gait measurements would provide good predictors of 
hippocampal atrophy. 
We divided 22 MCI subjects into two groups: a stable group and a decliner group 
based on medial temporal lobe (MTL) volume changes measured using the EXACT 
method (Chapter 2).  This resulted in 14 subjects being classified as stable and 8subjects 
being classified as declining. The baseline data matrix consisted of gait measurements, 
neuropsychological measurements, and brain volumetrics. A principle component 
analysis (PCA) was applied to the data matrix to extract principle components (PCs).We 
selected the PCs that had eigenvalues greater than one. Then, the data matrix was 
multiplied with the PCs to produce projection data. A machine learning method was then 
applied to predict hippocampal atrophy (two groups) using the projection data from the 
PCA. A support vector machine (SVM) was used on the projection data to classify 
subjects as stable or declining using either baseline measurements or the change in gait 
and neuropsychological measurements over 18 months. In the analysis of the baseline 
data, gait measures had the highest overall accuracy (0.74), sensitivity (0.66), and 
specificity (0.75) for identifying hippocampal atrophy. Adding baseline brain volumetrics 
or neuropsychological assessments did not improve the overall accuracy, sensitivity, and 
specificity of the gait measurements. While, in the 18 months change analysis, the 
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neuropsychological measurements achieved the highest overall accuracy (0.72), 
sensitivity (0.32), and specificity (0.89). The addition, the gait measurements did not 
improve the overall accuracy, sensitivity, and specificity. In the baseline analysis, the gait 
velocity, and stride velocity during single and dual tasks were the most important 
measurements.  Examining changes over 18 months, the digit span test forward and 
backward tests had the highest predictive values.  Although there were limitations to this 
study to the small sample size, the study highlights to potential value of gait 
measurements as a predictor of hippocampal atrophy.   
5.2 Recent Developments of Imaging Biomarkers 
Imaging biomarkers play an important role in improving our understanding of 
Alzheimer disease and its staging. More importantly, biomarkers will improve diagnosis 
of the disease in its earliest stages and will be necessary to evaluate the effectiveness of 
different therapeutic approaches. In addition to the detection of brain structural atrophy in 
AD using MRI and the detection of hypometabolism using FDG-PET, other modalities 
have been recently developed that may be more effective in the detection of AD 
pathology. These methods include the direct detection of amyloid beta and tau using 
PET,4,5 resting state fMRI, and perfusion imaging using MRI.6-8 The success of PET 
amyloid β imaging with Pittsburgh compound B (PiB) has translated into the clinical 
setting as a promising biomarker. Recently, alternative Aβ tracers have been developed 
including Florbetapir or [18F]-AV-45 with half-life of 110 minutes that is more 
accessible to imaging sites for the detection of Aβ.9 Several tau radio-ligands (18F-
THK5105, 18F-5117, 18F-T807 and 18F-T808) also showed higher binding affinity to tau 
in Alzheimer disease compared to healthy controls.10 More advance MRI methods have 
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also been developed including the use of resting state functional connectivity (FC) in the 
default mode network (DMN).  Specifically, declines in FC have been associated with the 
early stages of Alzheimer’s disease,11 suggesting that resting-state fMRI may be a 
promising biomarker for AD.12 Furthermore, measurements of cerebral blood flow (CBF) 
using arterial spin labelling (ASL) perfusion, as part of a MRI protocol may improve the 
detection of early Alzheimer’s disease pathology. Decreased CBF in subjects with AD 
has been associated with increased amyloid-β load6 and CBF measurement was shown to 
predict Aβ accumulation in early MCI subjects.7 Measuring the subfields of the 
hippocampus using MRI has also been investigated recently. Several research groups 
have developed high-resolution MR sequences to assess the hippocampus in vivo at sub-
millimetre resolution on coronal slices13-15 and incorporated automated segmentation 
methods16,17 to delineate hippocampal subfields, a technique that has great potential in the 
study of Alzheimer’s disease. Combining multiple imaging modalities will provide the 
most complete assessment of brain structure and function as an individual ages, and if 
Alzheimer’s disease takes hold. 
 Advances in high resolution-imaging and segmentation of the brain continue to be 
made at a record pace.   Hippocampal atrophy has been associated with memory loss in 
AD subject for more than two decades.18,19 Manual segmentation of the hippocampus has 
significant variation due to different anatomical boundaries of this region.20 However, it 
is gold standard in neuroanatomical image segmentation and it is time consuming and 
subjective particularly in large data sets. Therefore, an effort has been made to establish a 
reference standard of hippocampus volume that can be used to compare different 
methodologies with these harmonization initiatives.21-23 Related to the methods presented 
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in this thesis, other studies have recently shown that the use of multiple atlases can 
improve segmentation reliability compared to single atlas based models.24-26 Each atlas 
image is registered to a subject image and label propagation is used to produce multiple 
labels of the subject image. Finally, label fusion methods including simple majority vote, 
cross-correlation weighted majority vote, and normalized mutual information weighted 
majority vote is performed to merge these labels of the subject image. For example, 
Nestor et. al.27 used 5 protocols of hippocampus segmentation to find their automated 
segmentation method can easily adopt to different hippocampus segmentation definition. 
They used affine registration to find highest ranked the anterior commissure–posterior 
commissure (AC-PC) atlases (n=100) into the subject image using cross-correlation. 
Next, a deformable registration was applied to propagate the atlas hippocampal labels to 
the subject image. Finally, non-weighted vote-rule was used to combine the best 15 
binary templates into subject image. Therefore, there is improvement room within 
multiple–atlas based approach, which may include atlas selection, atlas to target matching 
scheme, registration parameters and label fusion strategies. Some multiple-atlas based 
approaches use large numbers of manually segmentation atlases that take significant time 
for nonlinear registration and perform different label fusion strategies. For example, 
Aljabar et. al.24 used 275 atlases with simple majority vote to obtain a Dice index of 0.83 
compared with manual segmentation in healthy subjects. Previous studies performed 
using 80 atlases26 with simple majority vote and 30 atlases28,29 on healthy controls 
obtained overlap measurements of 0.89, 0.88 and 0.82. Barnes et. al.30 showed a Dice 
index of 0.86 on healthy controls and AD subjects using 55 atlases. In addition, the patch-
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based label fusion method31 provided a 0.84 overlap measurement in ADNI data using 20 
atlases.  
Recently, one group (Pipitone et. al.) showed investigated a small number of atlases  
(<10) in combination of three label fusion methods (cross-correlation, normalised mutual 
information-based weighted label fusion and simple majority vote label fusion). Pipitone 
et. al.32 used 9 atlases with label fusion to achieve a Dice index of 0.84 between 
automated and manual segmentation of the hippocampus.  They found there was not 
significant effect between three label fusions while multi-atlas segmentation methods 
found the cross-correlation and normalized mutual information based weighted label 
fusion improves segmentation reliability compared to simple majority vote label fusion.  
In addition, development of segmentation algorithm can be appropriate tool to use in 
imaging study. The change in volume of this structure is likely to be a sensitive indicator 
of Alzheimer disease (AD) progression. Although several methods are available to 
measure brain volumes including FreeSurfer, results show a tendency of this method to 
overestimate hippocampus volume. In addition, some approaches often use a large 
number of manually segmented atlases that take significant time and expert skill to 
generate. In comparison, the fully automated EXACT method developed and described in 
this thesis used 8 atlases, which provide improvements in speed compared to methods 
that use larger numbers of atlases. Multiple atlas labels were not merged and the best-
matched atlas label was selected using normalized mutual information in region of 
interest for each subject image. The rationale for including different groups (NEC, MCI 
and AD) in atlas date set was to include more representative morphological variation. 
Also, the EXACT didn’t use specific hippocampus definition protocol instead, was 
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guided by anatomical structures and refined using clearly identifiable tissue boundaries 
observed in T1-weighted images. The method also produced a robust marker of medial 
temporal lobe atrophy that was sensitive to different rates of atrophy over two years.  
Further comparisons with other methods are needed to determine under what conditions 
the EXACT method is preferred. 
 
Functional MRI may provide useful information regarding the functional 
connectivity of various brain networks including those involved in memory and other 
cognitive domains. BOLD fMRI is an indirect measure of neuronal activity, which 
reflects the integrated synaptic activity of neurons through MR signal changes resulting 
from changes in blood flow, blood volume, and the blood oxyhemoglobin/ 
deoxyhemoglobin ratio. In this thesis, a novel measurement of neuronal activity was 
generated from resting-state functional magnetic resonance imaging data.  This measure 
is not a metric of functional connectivity.  Rather it is based on the fluctuation of the 
blood oxygen level dependent (BOLD) signal over time. This new neuronal activity 
marker has some similarities to glucose metabolism measured by FDG-PET.  In this 
thesis, we illustrated the association between this neuronal activity biomarker and glucose 
uptake in healthy elderly and people with Alzheimer’s disease.  We also demonstrated for 
the first time that the new neuronal activity biomarker could differentiate people with 
Alzheimer’s disease and healthy controls.  The results presented in this thesis are only the 
starting point for the evaluation of this measurement.  Although promising, the sensitivity 
and specificity must now be compared to other potential biomarkers of disease to assess 
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whether this measurement has potential benefits.  Such an MRI marker could be easily 
adopted due to the wide accessibility and low cost of MRI. 
   
5.3 Conclusions 
The overall goal of this thesis was to develop and validate new potential structural 
and functional biomarkers of Alzheimer disease (AD) that would improve diagnosis and 
predict disease progression. In chapter 2, we showed that a fully automated longitudinal 
segmentation method provided a robust marker of brain atrophy that was sensitive to 
different rates of atrophy over two years between NEC, MCI, and AD groups. 
Furthermore, in Chapter 3our goal was to develop a new biomarker of brain function 
based on the fluctuation of the magnitude of the RS-fMRI signal. Using this approach we 
found lower brain activity in people with mild Alzheimer disease compared to healthy 
subjects. In a pixel-by-pixel analysis of gray matter voxels, this brain activity metric 
derived from RS-fMRI was also found to be strongly correlated with glucose metabolism 
measured by FDG-PET. The observed positive correlation between the newly defined 
biomarker of neuronal activity measured by RS-fMRI and the MMSE score also suggest 
that this biomarker was related to cognitive performance. Therefore, including this 
straight forward measurement of neuronal activity by RS-fMRI may increase the 
reliability of detecting Alzheimer’s disease. Overall, these two chapters showed the 
volume changes of the MTL and the neuronal activity measurements from RS-fMRI 
could be help improve the detection of AD and monitor progression. 
In the final study within this thesis we determinedwhether gait and cognitive 
measures could predict or were associated with medial temporal lobe atrophy. Medial 
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temporal lobe atrophy over 18 months was evaluated using the novel method developed 
in Chapter 2. This study provided preliminary evidence that gait is impaired people with 
mild cognitive impairment who proceed to have hippocampal atrophy within 18 months 
of measurement.  Gait analysis could help to predict future hippocampal atrophy. 
5.4 Future Directions 
The field of imaging biomarker development continues to advance at a rapid pace.  
Measurement of brain atrophy is unlikely to be an early indicator of disease, but will 
continue to play an important role in monitoring disease progression and treatment 
response.  Although the hippocampal / medial temporal lobe region is one of the first 
areas that is affected in Alzheimer disease, future work should evaluate the combined use 
of multiple regions using the EXACT methodology including other subcortical areas 
(amygdala, caudate nucleus). The exact method could also be improved.  For example, 
only a small number of atlases were used (eight) in the EXACT method. Including more 
atlases may further increase the robustness of the technique in cases of extreme 
anatomical variability, however would also increase computation time. Optimizing the 
number of atlases will be the focus of future work. The number of atlases used can 
impact the quality of the final segmentation. Combining information from multiple 
regions may increase detection sensitivity, but more importantly, may also improve 
ability to differentiate Alzheimer’s disease from other forms of dementia including 
Fronto-temporal dementia. 
New and more sensitive imaging metrics may allow for earlier detection and 
assessment of disease modifying therapies. Continued development of novel imaging 
modalities would provide complimentary information to existing methods for early 
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detection of AD. The brain activity metric that we developed could be further improved 
by improving the registration of the fMRI images to the MR anatomical images. 
Furthermore, other features including first and second order statistics and wavelet 
coefficients may be useful in for measuring brain activity based on the RS-fMRI signal. 
The differentiate performance of different features between mild AD and healthy subjects 
could be evaluated in terms of accuracy, sensitivity and specificity. Resting state fMRI 
has provided new insights related to the functional architecture of the brain in other brain 
disorders including epilepsy, schizophrenia, and depression. It would be interesting to 
apply new biomarker of brain activity to these other clinical populations. 
Definitive diagnosis of AD can only be made post-mortem from brain tissue. 
Therefore, determining the disease severity various stages including early MCI, late MCI, 
and AD using clinical/neuropsycholgical variables is critical. This information allows us 
to evaluate imaging biomarkers as predictors that can define the stage of the disease.  
However, to accomplish this goal, large databases are required that follow subjects over 
long periods of time, such as the ADNI database. Continued acquisition of standardized 
imaging protocols such as MRI, fMRI and PET in such cohorts will be an enormous asset 
to assess impact on predictive ability for new imaging analysis methods.  
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